TSANZ home

Results for "Boehringer Ingelheim New Zealand Primary Care Grant"

Home 5 Search query for: Boehringer Ingelheim New Zealand Primary Care Grant
Results for "Boehringer Ingelheim New Zealand Primary Care Grant"
VOLUME 6.02 – FEBRUARY 2021

VOLUME 6.02 – FEBRUARY 2021

Research Roundup:

February 2021

Welcome Message

We hope you’ve been keeping safe and well.

We are pleased to announce that the Boehringer Ingelheim New Zealand Primary Care Grant is now open. This grant aims to support research in respiratory health within the primary care sphere in New Zealand. Primary care can include general practice, allied health services, nursing in community health and community pharmacy.

Please note that a number of awards are closing this Wednesday 24 February. These include our modified travel awards that take into account travel bans and restrictions.

Don’t forget to register for our first ever Virtual Annual Scientific Meeting – TSANZSRS21.

Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

Enjoy the February edition of your Research Roundup.

Prof Sandra Hodge
Chair, Research Sub-Committee

Open Awards

Thoracic Society Awards

TSANZ Indigenous Respiratory Nursing Award – closing 01 April 2021

Boehringer Ingelheim New Zealand Primary Care Award – closing 05 April 2021

TSANZ National Asthma Council Australia – Asthma & Airways Fellowship – closing 31 May 2021

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Grifols Scientific Awards

The 18th Annual ALTA Alpha-1-Antitrypsin Laurell’s Training Award is now open.

Deadline for submission of letter of intent – 1 March 2021

Deadline for submission of full proposal – 31 May 2021

Registrations open for ASM

Registrations are now open for our first ever Virtual Annual Scientific Meeting! Be a part of TSANZSRS21 on 1-2 May 2021 from the comfort of your own home.

Respirology – Editor’s Choice

Respirology Issue 26.2 February 2021

Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial

Matthias H. Urban, Nicole Kreibich, Andreas Gleiss, Georg-Christian Funk, Sylvia Hartl and Otto C. Burghuber

DOI: 10.1111/resp.13914

 ASCOT trial

ASCOT is a clinical trial that will generate clinical evidence about the most effective treatments and combinations of treatments for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand, Indian and Denmark. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

Potential Treatments for COVID-19

The global response to COVID-19 is working to accelerate diagnostics, vaccines and therapeutics. While remdesivir has been shown to accelerate time to recovery, and low-dose dexamethasone to decrease mortality, more effective therapies are needed.

ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

ASCOT Trial Intervention

ASCOT ADAPT includes 3 treatment domains:

Domain A (Antiviral)

  1. Standard of care
  2. Standard of care + nafamostat

Domain B (Antibody)

  1. Standard of care
  2. Standard of care + convalescent plasma

Domain C (Anticoagulation)

  1. Standard dose thromboprophylaxis
  2. Intermediate dose thromboprophylaxis
  3. Standard dose thromboprophylaxis plus aspirin

Eligible patients can be randomised to one or more domains concurrently.

Protocol documents and further details are available at www.ascot-trial.edu.au

Surveys and Research

SURVEY OF LUNG CANCER CARE IN AUSTRALIA

We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

  • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
  • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
  • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

Thank you for your time.

Prof Fraser Brims
Curtin Medical School
fraser.brims@curtin.edu.au 

TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

This study has now been completed and below is a summary of the findings from this work.

The top 3 priorities rank by people with PF and caregivers were:

  1. What medications can reverse scarring in the lungs of people with PF?
  2. What medications can improve lung function in people with PF?
  3. What are the causes of PF?

The top 3 priorities rank by people with healthcare professionals/researchers were:

  1. What medications can reverse scarring in the lungs of people with PF?
  2. How can we prevent PF?
  3. What are the causes of PF?

The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

(click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

Yours sincerely,

Anne Holland
Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

TBPod

The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

Can you help TSANZ make a difference?

Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

1. Making a donation to our Benevolent Fund

The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

2. Making a donation to support research

With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

3. Establishing a named award

For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

4. Leave TSANZ a gift in your will

If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

5. TSANZ New Zealand Branch Incorporated 

New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
CLICK HERE to make a donation.

Thank you for your continued support of TSANZ.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 5.06 – SEPTEMBER 2020

Research Roundup:

September 2020

Welcome Message

Welcome to another edition of our TSANZ Research Roundup. We hope that you remain well during this difficult time, and our thoughts are especially with our Victorian members who are on the front-line treating patients with COVID or facing unprecedented restrictions.

Plans for our exciting first virtual ASM in 2021 are well underway, with abstract submissions opened on 21 September 2020 and registrations opening on 22 October 2020. Please visit our TSANZSRS2021 website for more details about abstracts, and pay close attention to the closing date of 6 November 2020. Abstracts submitted to the 2020 Annual Scientific Meeting are eligible to be resubmitted for the 2021 Annual Scientific Meeting, and all resubmitted abstracts will undergo the same robust peer review process for allocation to oral or poster sessions.

The TSANZ Webinar Series continue, with the Society Medal and 50th Anniversary Medalpresentations on 30 September, so don’t forget to register for these exciting events.  

Please also note the opening of the following awards that are now accessible on the TSANZ Awards Submission Portal:

  • Past Presidents Scholarship Award: this new award will support national or international travel costs to present research for early career researchers who do not have the resources available to them via their institution or workplace. Importantly, the awardee will have the support from a TSANZ Past President who will provide invaluable feedback and professional development guidance to help them develop their research presentation skills.
  • Boehringer Ingelheim New Zealand Primary Care Grant: this award addresses the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic.

In addition, we are pleased to announce the new CREATE PhD Scholarship, and the opening of LFA Awards:

Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

Enjoy the September edition of your Research Roundup.

Prof Sandra Hodge

Chair, Research Sub-Committee

Call for Abstracts

Abstracts for TSANZSRS21 are now open. Abstracts submitted to the 2020 Annual Scientific Meeting are eligible to resubmit for the 2021 Annual Scientific Meeting. Please note, all resubmitted abstracts will undergo the same robust peer review process for allocation to oral or poster sessions.

Please submit your abstract by 6 November and join us for our first ever virtual ASM in 2021!

 

New Award: CREATE Hope Research Fund PhD Scholarships in Pulmonary Fibrosis

The CREATE PhD Scholarships in Pulmonary Fibrosis will support research into pulmonary fibrosis in Australia

Relevant domains of research inquiry include any form of clinical, population, laboratory, genetic or tissue based research. 

Students who are wishing to undertake a PhD, or are currently enrolled in a PhD in Pulmonary Fibrosis Research, are invited to submit an application. The student must be a resident in Australia throughout the period of the research program.

The Centre of Research Excellence in Pulmonary Fibrosis (the CRE-PF)  will allocate a total of two grants, each of $28,000, for the PhD Scholarships. These scholarships will either fund a stipend for one year for a full time student or may be extended over a second year, should the student be able to secure matching funds to permit extension of the period via their University or Research Institute. Extension of the funding in order to extend the value of the research investment by the Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) and Lung Foundation Australia by securing matching funding from the host institution is encouraged and will be regarded favourably.

These funds are to be used for the student stipend. Direct, indirect research costs and/or infrastructure costs do not form part of this grant and will not be covered by this funding.

Click here for more info!

Open Awards

Thoracic Society Awards

TSANZ Past Presidents Scholarship Award – closing 04 October 2020

Boehringer Ingelheim New Zealand Primary Care Grant – closing 04 October 2020

TSANZ ASM 2021 abstract-linked Awards – closing 6 November 2020

 Lung Foundation Awards

Lizotte Family Idiopathic Pulmonary Fibrosis Research Grant – closing 13 October 2020

Ludwig Engel Grant-in-Aid for Physiological Respiratory Research – closing 13 October 2020

Ivan Cash Grant-in-Aid For Idiopathic Pulmonary Fibrosis Research – closing 13 October 2020

Cochrane Airways Australia Scholarship – closing 13 October 2020

Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF)

CREATE Hope Research Fund PhD Scholarships in Pulmonary Fibrosis – closing 31 October 2020

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Respirology – Special Issue and Editor’s Choice
 

Respirology Issue 25.9 September 2020

 

Special Issue: Interventional Pulmonology Pearls

 

Cover caption: A collection of images from the Invited review series International Pumlonology Pearls.

Illustrations credit (A to F clockwise from top left) : A and B: Pyng Lee (personal communication), C and D: Fielding and Oki p.914, E: Guibert et al. p.953, F: Shah and Slebos p.972.

DOI: 10.1111/resp.13598

 

Respirology Issue 25.10 October 2020

 

Acute effects of e-cigarette vaping on pulmonary function and airway inflammation in healthy individuals and in patients with asthma

Serafeim-Chrysovalantis Kotoulas, Athanasia Pataka, Kallipoi Domvri, Dionisios Sypratos, Paraskevi Katsaounou, Konstantinos Porpodis, Evangelia Fouka, Aikaterini Markopoulou, Katalin Passa-Fekte, Ioanna Grigoriou, Theodoros Kontakiotis, Paraskevi Argyropoulou and Despoina Papakosta

 

Cover caption: Asthmatic and healthy smokers underwent pulmonary function tests to assess acute effects of e-cigarettes

DOI: 10.1111/resp.13806

 

Peer Connect Service for people with pulmonary fibrosis in Australia: Participants’ experiences and process evaluation

Gabriella Tikellis, Joanna Y.T. Lee, Tamera J. Corte, Jamie Maloney, Michael Bartlett, Tonia Crawford, Ian N. Glaspole, Nicole Goh, Kelcie Herrmann, Alison J. Hey-Cunningham, Greg Keir, Yet H. Khor, John Price, Debra G. Sandford, Lissa Spencer, Alan Teoh, Jennifer Walsh, Susanne Webster and Anne E. Holland

 

Cover caption:  Bill, diagnosed with IPF in 2015, is a primary peer within the Pulmonary Fibrosis Peer Connect service. (Photograph credit: Lung Foundation Australia)

DOI: 10.1111/resp.13807

Invitations and surveys

BREATHE Study

Do you have asthma, emphysema, chronic bronchitis or bronchiectasis?

Do you live in an area affected by bushfires or bushfire smoke?

If yes to both, you may be eligible for the BREATHE study.

We are studying facemasks for prevention of smoke exposure

Find out more: https://kirby.unsw.edu.au/breathe

Please register your interest: https://www.surveymonkey.com/r/C96DXJN

Contact us: e.kpozehouen@unsw.edu.au

Ethics Approval: HC200477

INVITATION TO PARTICIPATE IN AN ERS STUDY AIMING TO IMPROVE THE QUALITY OF CLINICAL TRIALS EVALUATING THE MANAGEMENT OF COPD EXACERBATIONS

Dear colleagues,

Clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations evaluate heterogeneous outcomes (endpoints), often omitting those that are clinically important and relevant to patients. This limits their usability and comparability.

To remedy this issue, the European Respiratory Society (ERS) set-up a Task Force aiming to develop a core outcome set (COS). A COS is a consensus-based minimum set of clinically important outcomes that should be evaluated in all future clinical trials on the management of COPD exacerbations.

We have identified around 50 outcomes of COPD exacerbations and we need your help to prioritize a small number of the most important outcomes, to be included in the core outcome set and to be evaluated in all future clinical trials on the management of COPD exacerbations. To help us prioritize the outcomes, we will be grateful if you could complete a survey that has two stages, 4-8 weeks apart. Each survey takes about 20 minutes to complete.

In the first survey, you will be asked to rate the importance of 50 outcomes between 1-9:

  • 1-3: Outcomes of limited importance.
  • 4-6: Outcomes that are important but not critical.
  • 7-9: Critical outcomes.

We welcome responses from health professionals, researchers, patients with COPD and any other stakeholders with interest in COPD exacerbations.

In the second survey, you will see a graph summarizing the responses of all participants in the first survey and you will be asked to reconsider your ratings, taking into consideration the views of the other responders. While the aim of this survey will be to reach consensus, you will not have to change your ratings if you do not want to.

Your opinion in both surveys is extremely important in developing the core outcome set.

It is crucial that you complete both surveys and we would be very grateful if you can do this.

Please, take the survey in one of the following languages:

English: https://delphimanager.liv.ac.uk/COPD/
Portuguese: https://delphimanager.liv.ac.uk/COPD-PO/
German: https://delphimanager.liv.ac.uk/COPD-GE/
Hungarian:  https://delphimanager.liv.ac.uk/COPD-HU/
Mandarin: https://delphimanager.liv.ac.uk/COPD-CN/
Spanish: https://delphimanager.liv.ac.uk/COPD-ES/
Russian: https://delphimanager.liv.ac.uk/COPD-RU/
Greek: https://delphimanager.liv.ac.uk/COPD-GR/
Danish: https://delphimanager.liv.ac.uk/COPD-DK/
Italian: https://delphimanager.liv.ac.uk/COPD-IT/

We appreciate this is a difficult time for patients and professionals in the respiratory community. While all efforts should rightly be focused on caring for those affected by the novel coronavirus and COVID-19, we believe that research to improve care and outcomes for respiratory patients is needed now more than ever. We are sensitive to the enormous pressures faced by patients and professionals in our community and will review the timelines for this survey and subsequent work in response to the ongoing global pandemic.

Thank you very much in advance,
Kind regards,
Associate Prof. Jens-Ulrik Jensen,
Dr. Alexander Mathioudakis,
Prof. Jørgen Vestbo,
On behalf of the study team.

 

GLOBAL CURRENT PRACTICES OF MECHANICAL VENTILATION MANAGEMENT IN COVID-19 PATIENTS

Dear Colleague, 

You are invited to partake in the current study, “Global Current Practices of Mechanical Ventilation Management in COVID-19 Patients.” The goal of this study is to explore the current practices of mechanical ventilation support in adult COVID-19 patients worldwide. 

We are carrying out this online survey for frontline clinicians involved in the care of patients with COVID-19, with the aim to examine which ventilation techniques healthcare providers’ used to manage adult COVID-19 patients. It would be helpful if you could complete this survey, the estimated time is 5-10 minutes. While there is limited information available on ventilatory support practices in COVID-19 patients, this international survey will provide further insights into current strengths and limitations of global practices.

Rest assured that your answers will be kept confidential, and no information will be used to identify you or your response. This research project was approved by the Institutional Review Board (IRB), AFHER-IRB-2020-012.

If you have any concern or question regarding this study, please do not hesitate to contact me at Jaber.alqahtani.18@ucl.ac.uk.

THANK YOU!
Jaber Alqahtani
On behalf of the whole international team

 

INVITATION TO PARTICIPATE IN A STUDY ON SELF MANAGEMENT FOR PULMONARY FIBROSIS: WHAT DOES IT MEAN AND HOW MIGHT IT HELP?

Dear Members of the Thoracic Society of Australia and New Zealand, 

Alfred Health and the Centre of Research Excellence in Pulmonary Fibrosis are inviting health professionals involved with pulmonary fibrosis (PF) to take part in a study on self-management for pulmonary fibrosis: what does it mean and how might it help? 

Participation is voluntary and involves you sharing your views, opinions and experiences on the patients’ management of PF through a confidential telephone interview of about 30 minutes in duration

Your perspective is important to help us identify and develop resources that will provide patients with the knowledge and tools to manage their own wellbeing. In turn, this will help health professionals to be better equipped to provide support to people with PF and their families. 

The study has been approved by the Alfred Health Human Ethics Committee (Project number: 144/20). 

If you are interested in participating or would like further information on this study, please contact: 

Professor Anne Holland (Chief Investigator) 
Professor of Physiotherapy, 
Monash University and Alfred Health 
Email: Anne.Holland@monash.edu 
Telephone: (03) 9903 0214 

Ms Joanna Lee (PhD candidate)
Monash University and Alfred Health
Email: joanna.lee2@monash.edu
Mobile: 0431 689 361

Thank you for your time and consideration of our study. 

ASCOT trial

ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

Potential Treatments for COVID-19

There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

ASCOT Trial Intervention

Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

  1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
  1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

Protocol documents and further details are available at www.ascot-trial.edu.au

 

Can you help TSANZ make a difference?
 

Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

1. Making a donation to our Benevolent Fund

The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

2. Making a donation to support research

With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

3. Establishing a named award

For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

4. Leave TSANZ a gift in your will

If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

5. TSANZ New Zealand Branch Incorporated 

New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
CLICK HERE to make a donation.

Thank you for your continued support of TSANZ

.

 

VOLUME 6.02 – FEBRUARY 2021

VOLUME 5.05 – AUGUST 2020

Research Roundup:

August 2020

.

Welcome Message

Welcome to the August Research Roundup. We hope you are all staying well in these uneasy COVID-19 times.

This month we are pleased to open two new awards. Firstly, we are very excited to announce and gratefully acknowledge the generous donation from our immediate past president, Prof Allan Glanville, to establish the Past Presidents Scholarship Award. We hope that others will join him in supporting this award that will provide both funding for our ECRs and, provide access to professional mentors and networks. Given global travel restrictions, ECRs are encouraged to think creatively when applying and consider the merit in visiting institutions closer to home.

Secondly, we would like to thank Boehringer Ingelheim New Zealand for supporting a new award for our New Zealand members. The Boehringer Ingelheim New Zealand Primary Care Grant aims to support research which will address the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic. Primary care can include general practice, allied health services, community health and community pharmacy.

As you would be aware, TSANZ is part of the National COVID-19 Clinical Evidence Taskforce; a living guideline which is continuously updated as new peer reviewed research becomes available. Many of our members are contributing to the COVID-19 research effort. One large multi-centre trial is the ASCOT trial (AustralaSian COVID-19 Trial) which many of our members are involved in. This trial will which be featured in a TSANZ webinar on 17 September 20.

We are pleased to again be hosting the LFA Awards. These will be opening on the 1st of September, including the Lizotte Family Research Award for IPF Research; Ludwig Engel Grant-in-Aid for Physiological Research; Ivan Cash Grant-in-Aid for IPF Research; and the Cochrane Airways Australia Scholarship. Please see below for more details.

As TSANZ members we also have the privilege of participating in an increasing number of surveys as detailed below. These include surveys of the Breathe Study: Investigating the role of masks for patients with asthma and COPD against bushfire smoke, Cystic Fibrosis Australia Research and Advocacy Priority Setting, and studies aimed at improving the quality of clinical trials evaluating  the management of COPD exacerbations, nurses’ attitudes to caring for people with intellectual disability, global current practices of mechanical ventilation management in COVID-19 patients, self-management for pulmonary fibrosis and  identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of PF. These are all very worthy studies and we encourage your participation.

Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below

Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

Enjoy the August edition of your Research Roundup.

Prof Sandra Hodge

Chair, Research Sub-Committee

TSANZ Past President’s Award

The TSANZ Past Presidents Scholarship Award aims to support early career researchers (ECRs) who do not have the resources available to them via their institution or workplace to:

1)  Develop their presentation of research skills, and/or

2) Present their research at a national or international professional conference of their choice.

The Scholarship will cover

  • Airfares
  • Accommodation
  • Ground travel and transfers
  • Registration
  • Per Diem Daily Allowance in accordance with the ATO Reasonable Travel and Meal Allowance Guide

Up to a maximum of AUD 7000, with the amount to be paid dependent on the delivery of receipts for the expenses incurred above.

Additionally, the Scholarship will provide the awardee with support from a TSANZ Past President to review their presentation and provide feedback and professional development on research presentation skills. The Past President will be determined by TSANZ.

Please visit the TSANZ Awards Submissions Portal for more information.

Boeringer Ingelheim New Zealand Primary Care Grant

The Boehringer Ingelheim New Zealand Primary Care Grant aims to support research which will address the issue of access to primary care in New Zealand, particularly during restrictions like those faced during the COVID-19 pandemic.

Primary care can include general practice, allied health services, community health and community pharmacy.

The grant is valued at NZD 5000 and will support studies for one year only.

Please visit the TSANZ Awards Submissions Portal for more information.

CREATE Grant-in-Aid Funding Opportunity

In 2020, there is a CREATE Grant-in-Aid opportunity for the award of one or more grants valued at a total of $7,000 to assist new collaborative investigator led Pulmonary Fibrosis research within the group of CREATE Fellows. The objective of the CREATE Grant-in-Aid is to encourage new research which meets the aims of the CRE-PF and builds collaborations between CREATE Fellows drawn together through the CRE-PF.

Please visit the LFA Awards Submissions Portal for more information.

LFA Awards

Lung Foundation Australia and its partners are excited to announce the following Research Grants will be open to application from 1 September 2020. For more information visit: https://lungfoundation.com.au/research/awards-and-grants/apply-for-funding/

YEAR OPEN

YEAR UNDERTAKEN

Award 

Target area 

Value

Duration

Timeline

2020

2021

Lung Foundation Australia – Lizotte Family Grant for IPF Research 

IPF 

 $        5,000.00 

1 year

1 September 2020 (close 13 October, announced 11 Dec) 

2020

2021

Lung Foundation Australia – Ludwig Engel Grant-in-Aid for Physiological Respiratory Research

IPF 

 $        5,000.00 

1 year

1 September 2020 (close 13 October, announced 11 Dec) 

2020

2021

Lung Foundation Australia -Ivan Cash Grant-in-Aid For IPF Research

IPF 

 $        5,000.00 

1 year

1 September 2020 (close 13 October, announced 11 Dec) 

2020

2021

Lung Foundation Australia -Cochrane Airways Australia 
Scholarship

Systematic Review

$        2,500.00 

1 year

1 September 2020 (close 13 October, announced 11 Dec) 

 

LFA 2020 Research Grant recipients

 

Congratulations to the recipients of the Lung Foundation Australia 2020 Research Grants.

2019

2020

Lung Foundation Australia – Ellen Yates Memorial Grant in Aid for Lung Cancer Research

$20,000.00 

Edith Cowan University

Dr. Afaf Abed

2019

2020

Lung Foundation Australia – Deep Manchanda Fellowship in Lung Cancer Research

$   160,000.00 

The Garvan Institute of Medical Research

Dr. Venessa Chin

2019

2020

Lung Foundation Australia – Di Cox PhD Scholarship in IPF Research 

 $      45,000.00 

 University of Sydney

Dr. Laura Glenn

2019

2020

Lung Foundation Australia – Brian Eaton PhD Scholarship in IPF Research 

 $      45,000.00 

 University of Sydney

Dr. Matthew Parker

2019

2020

Lung Foundation Australia – Lizotte Family Grant for IPF Research

$        5,000.00 

Austin Health

Dr Yet Hong Khor

2019

2020

Lung Foundation Australia – Ludwig Engel Grant-in-Aid for Physiological Respiratory Research

$        5,000.00 

The Children’s Hospital at Westmead

Dr. Alexander Wong 

2019

2020

Lung Foundation Australia – Ivan Cash Grant-in-Aid For IPF Research

$        5,000.00 

RMIT University 

Dr. Paris Papagianis

2019

2020

Lung Foundation Australia – Cochrane Airways Australia 
Scholarship

$        2,500.00 

University of South Australia

Kelsey Sharrad

 

Australasian Severe Asthma Registry (ASAR) Annual Report 2019

 

TSANZ is excited to share the ASAR 2019 Annual Report with you!

In 2019, TSANZ in collaboration with the Australasian Severe Asthma Network (ASAN), successfully transitioned the Severe Asthma Web-based Database (SAWD) to ASAR – a Clinical Quality Registry (CQR). ASAR is now uniquely positioned to collect longitudinal data (10-year follow-up) on a well-characterised severe asthma cohort in Australia and New Zealand with the capability to add modules of specific interest, for example, the Australasian Benralizumab Registry.

To view the ASAR 2019 Annual Report please click here.

Respirology – Editor’s Choice 

Respirology Issue 25.7 July 2020

 

Sputum transcriptomics implicates increased p38 signalling activity in severe asthma

Katherine J. Baines, Michael Fricker, Vanessa M. McDonald, Jodie L. Simpson, Lisa G. Wood, Peter A.B. Warik, Heather E. Macdonald, Andrew Reid and Peter G. Gibson

 

The authorship team from Hunter Medical Research Institute, The University of Newcastle, Newcastle, Australia

DOI: 10.1111/resp.13749

 

Impact of chronic obstructive pulmonary disease on mortality: A large national cohort study

Hye Yun Park, Danbee Kang, Hyun Lee, Sun Hye Shin, Minwoong Kang, Sunga Kong, Chin Kook Rhee, Juhee Cho and Kwang Ha Yoo

 

The Korean COPD And Outcomes Study Team. From left to right: (Top) Kwang Ha Yoo, Danbee Kang, Sun Hye Shin, (Bottom) Juhee Cho and Hye Yun Park

DOI: 10.1111/resp.13678

Respirology Issue 25.8 August 2020

 

Ventilation heterogeneity and oscillometry predict asthma control improvement following step-up inhaled therapy in uncontrolled asthma

Francesca S.M. Tang, Sandra Rutting, Catherine E. Farrow, Katrina O. Tonga, Joanna Watts, Jessica R. Dame-Carrol, Amy Bertolin, Gregory G. King, Cindy Thamrin and David G. Chapman

 

The Airway Physiology and Imaging Group from the Woolcock Institute of Medical Research in Sydney, Australia, as part of the overall research team. From left to right: Prof. Gregory King, Dr David Chapman, Dr Sandra Rutting, Dr Katrina Tonga and A/Prof. Cindy Thamrin.

DOI: 10.1111/resp.13772

 

Identification and definition of asthma–COPD overlap: The CanCOLD study

Miriam Barrecheguren, Lancelot Pinto, Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Wan C. Tan, Pei Z. Li, Shawn D. Aaron, Andrea Benedetti, Kenneth R. Chapman, Brandie Walker, J. Mark Fitzgerald, Paul Hernandez, François Maltais, Darcy D. Marciniuk, Denis E. O’Donnell, Don D. Sin, Jean Bourbeau for The Cancold Collaborative Research Group and The Canadian Respiratory Research Network

 

The authorship team on behalf of the CanCOLD Collaborative Research Group and

the Canadian Respiratory Research Network. From top left to right bottom: Miriam Barrecheguren, Lancelot Pinto, Seyed-Mohammad-Yousof Mostafavi-Pour-Manshadi, Wan Tan, Pei Li, Shawn Aaron, Andrea Benedetti, Kenneth Chapman, B Walker, Mark Fitzgerald, Paul Hernandez, François Maltais, Darcy Marciniuk, Denis O’Donnell, Don Sin, Jean Bourbeau

DOI: 10.1111/resp.13780

Invitations and surveys

BREATHE Study

Do you have asthma, emphysema, chronic bronchitis or bronchiectasis?

Do you live in an area affected by bushfires or bushfire smoke?

If yes to both, you may be eligible for the BREATHE study.

We are studying facemasks for prevention of smoke exposure

Find out more: https://kirby.unsw.edu.au/breathe

Please register your interest: https://www.surveymonkey.com/r/C96DXJN

Contact us: e.kpozehouen@unsw.edu.au

Ethics Approval: HC200477

CYSTIC FIBROSIS RESEARCH AND ADVOCACY PRIORITY SETTING SURVEY 2020 AND BEYOND

Dear Members of the Thoracic Society of Australia and New Zealand,

Cystic Fibrosis Australia (CFA) is inviting the TSANZ members to take part in their Research and Advocacy Priority Setting survey. If you are a CF stakeholder, living with the condition or looking after someone who lives with the condition, then your survey responses are greatly needed and encouraged.

https://www.surveymonkey.com/r/F38Q8K2

We want all our community members, patients, carers, clinicians and researchers to be involved in every step and we thank you for agreeing to take part.

To speak to us about this questionnaire or for any further enquires, contact us at (02) 9889 5171 or email nickim@cfa.org.au. Alternatively, you can join the conversation over at the Cystic Fibrosis Australia page on Facebook.

 

INVITATION TO PARTICIPATE IN AN ERS STUDY AIMING TO IMPROVE THE QUALITY OF CLINICAL TRIALS EVALUATING THE MANAGEMENT OF COPD EXACERBATIONS

Dear colleagues,

Clinical trials evaluating the management of chronic obstructive pulmonary disease (COPD) exacerbations evaluate heterogeneous outcomes (endpoints), often omitting those that are clinically important and relevant to patients. This limits their usability and comparability.

To remedy this issue, the European Respiratory Society (ERS) set-up a Task Force aiming to develop a core outcome set (COS). A COS is a consensus-based minimum set of clinically important outcomes that should be evaluated in all future clinical trials on the management of COPD exacerbations.

We have identified around 50 outcomes of COPD exacerbations and we need your help to prioritize a small number of the most important outcomes, to be included in the core outcome set and to be evaluated in all future clinical trials on the management of COPD exacerbations. To help us prioritize the outcomes, we will be grateful if you could complete a survey that has two stages, 4-8 weeks apart. Each survey takes about 20 minutes to complete.

In the first survey, you will be asked to rate the importance of 50 outcomes between 1-9:

  • 1-3: Outcomes of limited importance.
  • 4-6: Outcomes that are important but not critical.
  • 7-9: Critical outcomes.

We welcome responses from health professionals, researchers, patients with COPD and any other stakeholders with interest in COPD exacerbations.

In the second survey, you will see a graph summarizing the responses of all participants in the first survey and you will be asked to reconsider your ratings, taking into consideration the views of the other responders. While the aim of this survey will be to reach consensus, you will not have to change your ratings if you do not want to.

Your opinion in both surveys is extremely important in developing the core outcome set.

It is crucial that you complete both surveys and we would be very grateful if you can do this.

Please, take the survey in one of the following languages:

English: https://delphimanager.liv.ac.uk/COPD/
Portuguese: https://delphimanager.liv.ac.uk/COPD-PO/
German: https://delphimanager.liv.ac.uk/COPD-GE/
Hungarian:  https://delphimanager.liv.ac.uk/COPD-HU/
Mandarin: https://delphimanager.liv.ac.uk/COPD-CN/
Spanish: https://delphimanager.liv.ac.uk/COPD-ES/
Russian: https://delphimanager.liv.ac.uk/COPD-RU/
Greek: https://delphimanager.liv.ac.uk/COPD-GR/
Danish: https://delphimanager.liv.ac.uk/COPD-DK/
Italian: https://delphimanager.liv.ac.uk/COPD-IT/

We appreciate this is a difficult time for patients and professionals in the respiratory community. While all efforts should rightly be focused on caring for those affected by the novel coronavirus and COVID-19, we believe that research to improve care and outcomes for respiratory patients is needed now more than ever. We are sensitive to the enormous pressures faced by patients and professionals in our community and will review the timelines for this survey and subsequent work in response to the ongoing global pandemic.

Thank you very much in advance,
Kind regards,
Associate Prof. Jens-Ulrik Jensen,
Dr. Alexander Mathioudakis,
Prof. Jørgen Vestbo,
On behalf of the study team.

 

NURSES’ ATTITUDES TO CARING FOR PEOPLE WITH INTELLECTUAL DISABILITY: AN AUSTRALIAN SURVEY

Dear Colleagues,

We invite you to consider participating in our online survey focused on nurses’ attitudes to caring for people with intellectual disability. This survey, led by researchers from Western Sydney and Central Queensland Universities, is a replication of a previous US study by Dr Melissa Desroches from the University of Massachusetts, Dartmouth.

People with intellectual disability have lower levels of general health than other members of our community. They also have higher incidence of hospitalisation and, of major concern, higher incidence of preventable death than members of the general population.

By learning about nurses’ attitudes to caring for people with intellectual disability, we anticipate being able to develop models of care and supportive resources for nurses to enhance the care that they provide to people with intellectual disability.

Please read the attached participant information sheet and consider completing this short survey by accessing the link below:

Caring for People with Intellectual Disability survey

Thank you for considering our invitation
A/Prof Nathan Wilson, Western Sydney University
Dr Peter Lewis, Western Sydney University
Ms Virginia Howie, Central Queensland University
Dr Melissa Desroches, University of Massachusetts, Dartmouth

Kind regards,
Virginia

 

GLOBAL CURRENT PRACTICES OF MECHANICAL VENTILATION MANAGEMENT IN COVID-19 PATIENTS

Dear Colleague, 

You are invited to partake in the current study, “Global Current Practices of Mechanical Ventilation Management in COVID-19 Patients.” The goal of this study is to explore the current practices of mechanical ventilation support in adult COVID-19 patients worldwide. 

We are carrying out this online survey for frontline clinicians involved in the care of patients with COVID-19, with the aim to examine which ventilation techniques healthcare providers’ used to manage adult COVID-19 patients. It would be helpful if you could complete this survey, the estimated time is 5-10 minutes. While there is limited information available on ventilatory support practices in COVID-19 patients, this international survey will provide further insights into current strengths and limitations of global practices.

Rest assured that your answers will be kept confidential, and no information will be used to identify you or your response. This research project was approved by the Institutional Review Board (IRB), AFHER-IRB-2020-012.

If you have any concern or question regarding this study, please do not hesitate to contact me at Jaber.alqahtani.18@ucl.ac.uk.

THANK YOU!
Jaber Alqahtani
On behalf of the whole international team

 

INVITATION TO PARTICIPATE IN A STUDY ON SELF MANAGEMENT FOR PULMONARY FIBROSIS: WHAT DOES IT MEAN AND HOW MIGHT IT HELP?

Dear Members of the Thoracic Society of Australia and New Zealand, 

Alfred Health and the Centre of Research Excellence in Pulmonary Fibrosis are inviting health professionals involved with pulmonary fibrosis (PF) to take part in a study on self-management for pulmonary fibrosis: what does it mean and how might it help? 

Participation is voluntary and involves you sharing your views, opinions and experiences on the patients’ management of PF through a confidential telephone interview of about 30 minutes in duration

Your perspective is important to help us identify and develop resources that will provide patients with the knowledge and tools to manage their own wellbeing. In turn, this will help health professionals to be better equipped to provide support to people with PF and their families. 

The study has been approved by the Alfred Health Human Ethics Committee (Project number: 144/20). 

If you are interested in participating or would like further information on this study, please contact: 

Professor Anne Holland (Chief Investigator) 
Professor of Physiotherapy, 
Monash University and Alfred Health 
Email: Anne.Holland@monash.edu 
Telephone: (03) 9903 0214 

Ms Joanna Lee (PhD candidate)
Monash University and Alfred Health
Email: joanna.lee2@monash.edu
Mobile: 0431 689 361

Thank you for your time and consideration of our study. 

 

IDENTIFYING BARRIERS AND FACILITATORS TO THE IMPLEMENTATION OF BEST PRACTICE FOR PULMONARY FIBROSIS IN AUSTRALIA

What are the barriers and facilitators to implementing best practice?

Dear Members of the Thoracic Society of Australia and New Zealand,

The Centre of Research Excellence in Pulmonary Fibrosis (CRE-PF) is inviting physicians involved in the management of people with pulmonary fibrosis (PF) to take part in our study aimed at identifying the barriers and facilitators to the implementation of best practice for the diagnosis, treatment and management of the disease.

Participation is voluntary and involves providing your views, opinions and experiences on the management of PF through confidential, in person interviews of about 30 minutes in duration. 

Your perspective is important to help us understand the barriers that may be impeding the implementation of best practice in clinical settings. The findings have the potential to guide the development of behaviour change strategies aimed at improving implementation and in turn, optimise the prognosis and management pathways for people with this insidious disease.

Like more information or interested in participating? Click here

The study has been approved by the Monash University Human Ethics Committee (Number 22350) and the Sydney Local Health District Human Ethics Committee (Number 2019/ETH13556).

If you would like to speak to us about any aspect of this study, please contact:

Professor Anne Holland
Professor of Physiotherapy, Monash University and Alfred Health
Department of Allergy, Clinical Immunology and Respiratory Medicine, Monash University
Anne.Holland@monash.edu or (03) 9903 0214

Thank you for your time and consideration of our study.

ASCOT trial

ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

Potential Treatments for COVID-19

There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

ASCOT Trial Intervention

Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

  1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
  1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

 

Protocol documents and further details are available at www.ascot-trial.edu.au

 

Can you help TSANZ make a difference?
 

Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

1. Making a donation to our Benevolent Fund

The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

2. Making a donation to support research

With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

3. Establishing a named award

For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

4. Leave TSANZ a gift in your will

If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

5. TSANZ New Zealand Branch Incorporated 

New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt. 
CLICK HERE to make a donation.

Thank you for your continued support of TSANZ.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 6.03 – MARCH 2021

Research Roundup:

March 2021

Welcome Message

We hope you’ve been keeping safe and well.

The TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship is now open. This award aims to facilitate the establishment of mid-career invenstigators as independent, self-directed researchers and to foster the development of high-quality respiratory research in Australia and New Zealand.

Please note that the TSANZ Indigenous Respiratory Nursing Award will be closing 12 April 2021 and the Boehringer Ingelheim New Zealand Primary Care Award will be closing 05 April 2021.

 

Don’t forget to register for our first ever Virtual Annual Scientific Meeting – TSANZSRS21.

Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

Enjoy the March edition of your Research Roundup.

Prof Sandra Hodge

Chair, Research Sub-Committee

Open Awards

Thoracic Society Awards

TSANZ Indigenous Respiratory Nursing Award – extended – closing 12 April 2021

Boehringer Ingelheim New Zealand Primary Care Award – closing 05 April 2021

TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship – closing 31 May 2021

  

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

2021 Australian Museum Eureka Prizes

Do you know someone making a difference in their field?

Entries to the 2021 Australian Museum Eureka Prizes are now open!

This year, there are 16 prizes on offer that cover a broad spectrum of scientific disciplines, which aim to recognise the achievements of scientists, researchers, and science communicators at all career stages.

There are prizes available for both individuals and teams, and entrants can either enter themselves or be nominated. The Eureka Prizes are open, but not limited to, those who work in research institutes, government departments, media, corporations, and universities. It’s free to enter and there’s a prize pool of $160,000 to be shared between the winners.

If you know an individual or team doing outstanding work, why not encourage them to enter?

Entries close 7pm AEST Friday 28 May

VIEW THE FULL PRIZE PROGRAM

Registrations open for ASM

Registrations are now open for our first ever Virtual Annual Scientific Meeting! Be a part of TSANZSRS21 on 1-2 May 2021 from the comfort of your own home.

Respirology – Editor’s Choice

Respirology Issue 26.3 March 2021

The impact of regular bisoprolol on the response to salbutamol in asthma: A double-blind randomized placebo-controlled crossover trial

Miriam R. Bennett, Catherina L. Chang, Chris Tuffery, Sandra Hopping and Robert J. Hancox

DOI: 10.1111/resp.13955

Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study

Tom J.C. Ruffles, Julie M. Marchant, Ian B. Masters, Stephanie T. Yerkovich, Danielle F. Wurzel, Peter G. Gibson, Greta Busch, Katherine J. Baines, Jodie L. Simpson, Heidi C. Smith-Vaughan, Susan J. Pizzutto, Helen M. Buntain, Gregory Hodge, Sandra Hodge, John W. Upham and Anne B. Chang

DOI: 10.1111/resp.13950

ASCOT trial

ASCOT is a clinical trial that will generate clinical evidence about the most effective treatments and combinations of treatments for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand, Indian and Denmark. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

Potential Treatments for COVID-19

The global response to COVID-19 is working to accelerate diagnostics, vaccines and therapeutics. While remdesivir has been shown to accelerate time to recovery, and low-dose dexamethasone to decrease mortality, more effective therapies are needed.

ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

ASCOT Trial Intervention

ASCOT ADAPT includes 3 treatment domains:

Domain A (Antiviral)

  1. Standard of care
  2. Standard of care + nafamostat

Domain B (Antibody)

  1. Standard of care
  2. Standard of care + convalescent plasma

Domain C (Anticoagulation)

  1. Standard dose thromboprophylaxis
  2. Intermediate dose thromboprophylaxis
  3. Standard dose thromboprophylaxis plus aspirin

Eligible patients can be randomised to one or more domains concurrently.

Protocol documents and further details are available at www.ascot-trial.edu.au

 Australasian Society for Medical Research message

The Thoracic Society is an affiliate member of the ASMR. Please see below for their latest communications.

Dear ASMR member

The Australian National Audit Office has informed us that an audit of ‘Health’s Management of the Medical Research Future Fund’ is currently open for contribution. The period for submissions is expected to close on 30 May 2021 and the audit report will be tabled in September 2021.

“The objective of this audit is to assess whether the Department of Health is effectively managing the Medical Research Future Fund (MRFF)” with respect to the following criteria:

  • “Are the MRFF governance arrangements effective?”
  • “Has MRFF legislation, governance, strategies and priorities guided selection of medical research initiatives?”
  • “Does Health effectively monitor, measure and evaluate MRFF’s performance?”

Submissions are confidential and can be anonymous (name, address and contact number fields provided are not required for a submission) so I encourage you and your extended networks to contribute instances or evidence around issues relating to the audit criteria for an ASMR submission (please send to president@asmr.org.au), or if you prefer, make a submission directly to the audit webpage.

While the addition of the MRFF to the health and medical research funding landscape is greatly welcomed, since its inception in 2014, Australian clinicians and researchers have expressed concerns about the MRFF processes and governance. I therefore cannot stress the importance of providing accurate, appropriate and verifiable submissions to the auditors with regard to the audit objective and criteria.

 

Yours sincerely,
Dr Ryan Davis
ASMR President 2021

Surveys and Research

SURVEY OF LUNG CANCER CARE IN AUSTRALIA

We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

  • These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
  • We are only asking for one response from each institution, we suggest it is the lead clinician for the lung cancer MDT.
  • Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE2021-0031).

Please follow the link to the Australian-wide Survey of Lung Cancer Care, or use the QR code below.

Thank you for your time.

Prof Fraser Brims
Curtin Medical School
fraser.brims@curtin.edu.au 

TOP 10 RESEARCH PRIORITIES FOR PULMONARY FIBROSIS

A recent research study as part of the NHMRC’s Centre of Research Excellence in Pulmonary Fibrosis grant aimed to identify the top 10 research priorities for pulmonary fibrosis (PF) according to people living with pulmonary fibrosis, caregivers, health professionals and researchers.

This study has now been completed and below is a summary of the findings from this work.

The top 3 priorities rank by people with PF and caregivers were:

  1. What medications can reverse scarring in the lungs of people with PF?
  2. What medications can improve lung function in people with PF?
  3. What are the causes of PF?

The top 3 priorities rank by people with healthcare professionals/researchers were:

  1. What medications can reverse scarring in the lungs of people with PF?
  2. How can we prevent PF?
  3. What are the causes of PF?

The findings from this study have been published in a peer-reviewed journal and will help guide future research directions.

(click on the link to view the paper– https://doi.org/10.1136/thoraxjnl-2020-215731)

The Study team extends their thanks and appreciation to all those who participated in the study for their time and valuable contribution to this work.

Yours sincerely,

Anne Holland
Professor of Physiotherapy (Research), Monash University (anne.holland@monash.edu)

TBPod

The TBPod are podcasts designed for clinicians and policymakers with an interest tuberculosis. These podcasts consist of conversations with expert clinicians, researchers, policy makers and advocates about their work in the field of tuberculosis. The TBPod is prepared by ACTnet and the TB Forum and can be found on ITunes, Spotify, and the ACTnet Website.

Can you help TSANZ make a difference?

Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

1. Making a donation to our Benevolent Fund

The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

2. Making a donation to support research

With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

3. Establishing a named award

For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

4. Leave TSANZ a gift in your will

If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

5. TSANZ New Zealand Branch Incorporated 

New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
CLICK HERE to make a donation.

Thank you for your continued support of TSANZ.

 

VOLUME 6.02 – FEBRUARY 2021

VOLUME 5.07 – DECEMBER 2020

Research Roundup:

December 2020

Welcome Message

Welcome to this month’s edition of our TSANZ Research Roundup.

This is a busy time for TSANZ and LFA’s research awards, with the Ann Woolcock New Investigator Award and LFA Ludwig Engel Research Award, Lizotte Family Research Award and Ivan Cash Research Awards currently under review. Keep your eyes open for several TSANZ awards opening soon! These will be accessible on the TSANZ Awards Submission Portal and include the new CFA Innovation Grant as detailed below. Also note NHMRC’s Special Initiative in Human Health and Environmental Change (SIHHEC). This will provide a catalytic stimulus to improve Australia’s current capability and capacity in human health and environmental change research, by supporting a single, multidisciplinary, nationally focused, collaborative network of researchers across Australia. The work of this network will help to protect the health of the Australian community and build a resilient and responsive health system. The focus includes improving current understanding of the complex interactions between primary, secondary and tertiary health effects of environmental and climate change.

Plans for our virtual ASM in 2021 are well underway, with registrations now open. Please visit our TSANZSRS2021 website for more details.

Finally, please consider helping us to provide essential funding for our world class respiratory researchers and for our TSANZ awards. You can leave a tax deductible donation of your choice in our areas of need, whether it be a donation to our Benevolent Fund or to support research, establishing a named award or leaving TSANZ a gift in your will. Details can be found below.

Please feel free to get in touch with the office if there is anything we can do to support your research needs during this time.

Enjoy the December edition of your Research Roundup.

Prof Sandra Hodge

Chair, Research Sub-Committee

Open Awards

Thoracic Society Awards

TSANZ Janet Elder International Travel Award – closing 15 January 2021

Boehringer Ingelheim New Zealand COPD Travel Award – closing 15 January 2021

TSANZ Peter Phelan Research Grant – closing 27 January 2021

TSANZ Rob Pierce Grant-in-Aid for Indigenous Lung Health – closing 27 January 2021

Maurice Blackburn Occupational Lung Disease Grant-in-Aid – closing 27 January 2021

Lung Foundations Awards

Cochrane Airways Australia Scholarship – closing 4 December 2020

Cystic Fibrosis Australia Awards

Australian Cystic Fibrosis Research Trust 2021 Innovation Grant – closing 29 January 2021

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Cystic Fibrosis Innovation Grant

Cystic Fibrosis Australia (CFA) is pleased to announce the 2021 Innovation Grant for post- doctoral researchers, currently working in cystic fibrosis (CF) research. This grant is awarded annually to one applicant for one year.

The Innovation Grant will allow a CF researcher to explore novel concepts at the initial feasibility stage.  Innovative applications relating to any aspect in the field of CF are encouraged, even those lacking pilot data.  The grant aims to allow the researcher to generate sufficient data within the one-year grant period to be in a position to apply for additional support from an appropriate funding body to continue the research.

The Innovation grant will be offered to post-doctoral researchers currently working in or proposing to work in CF research.  The researcher will have completed a research higher degree in CF or a related area within the last ten years.

The recipient of the Innovation Grant is required to provide progress reports on their research to CFA every six months.  In addition, and where appropriate, the recipient will be asked to make a presentation at a CFA conference (held every two years) in Australia.

The maximum amount awarded under the Innovation Grant will be $80,000.  The actual amount provided will be subject to approval of the applicant’s budget.

Applications can be made through the website of The Thoracic Society of Australia & New Zealand (TSANZ) and must be received by TSANZ no later than 5.00 pm (AEDT) 29th January 2021.

Registrations open for ASM

Registrations are now open for our first ever Virtual Annual Scientific Meeting! Be a part of TSANZSRS21 on 1-2 May 2021 from the comfort of your own home.

Respirology – Editor’s Choice

Respirology Issue 25.11 November 2020

 

Predictive value of control of COPD for risk of exacerbations: An international, prospective study

Marc Miravitlles, Pawel Sliwinski, Chin Kook Rhee, Richard W. Costello, Victoria Carter, Jessica H.Y. Tan, Therese S. Lapperre, Bernardino Alcazar, Caroline Gouder, Cristina Esquinas, Juan Luis García-Rivero, Anu Kemppinen, Augustine Tee, Miguel Roman-Rodrígues, Juan José Solder-Cataluña, David B. Price and on behlaf of the Respiratory Effectiveness Group (REG)

 

Cover caption: Control in COPD is a tool to assess clinical patient status and decision making on step-up or down treatment. Uncontrolled status is associated with an increased risk of exacerbations. This is a collaborative international study of REG, a not-for-profit initiative established by international experts in real-life and comparative effectiveness research in respiratory medicine

DOI: 10.1111/resp.13811

 

Disease progression across the spectrum of idiopathic pulmonary fibrosis: A multicentre study

Giacomo Sgalla, Erminia Lo Greco, Mariarosaria Calvello, Francesco Varone, Bruno Iovene, Stefania Cerri, Pierluigi Donatelli, Ada Vancheri, Mauro Pavone, Fabrizio Luppi, Carlo Vancheri and Luca Richeldi

 

Cover caption: The collaborative research team from three Italian centres in Catania, Rome and Modena. From left to right: Ada Vancheri, Carlo Vancheri, Bruno Iovene, Mauro Pavone, Giacomo Sgalla, Stefania Cerri, Francesco Varone, Luca Richeldi.

DOI: 10.1111/resp.13805

 

Respirology Issue 25.12 December 2020

 

 

Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic

David Langton, Joy Shia, Suzy Guo, Julie Sharp, Ceri Banks, Wei Wang, Virginia Plumber and Francis Thien

 

Cover caption:

Bronchial thermoplasty: Work in progress

DOI: 10.1111/resp.13830

 

Cost of hospitalisation for bronchiectasis exacerbation in children

Vikas Goyal, Steven M McPhail, Frank Hurley, Keith Grimwood, Julie M Marchant, I Brent Masters and Anne B Chang

 

Cover caption:

The emblem of AusBREATHE (Australian Bronchiectasis Centre of Research Excellence, especially for Aboriginal and Torres Strait Islander Children) is a reproduction of a painting by First Nations artist and former Menzies employee, who describes how the painting represents the lungs as follows:

‘When the earth was made, so were the first trees. They cleaned the air through their branches and leaves. The same is reflected in us with our lungs; they have branches like trees breathing in the air and cleaning our body and provide much needed oxygen.The butterflies represent a delicate balance; if something happens to the air, the butterflies will die. That’s why we must look after our air, like we have to look after our lungs because they keep us alive. The red dots represent alveoli that are at the end of the branches.’

DOI: 10.1111/resp.13828

Research Review

NZ Respiratory Research Review Issue 177

 

NZ Respiratory Research Review Issue 178

NZ Respiratory Research Review Issue 179

As part of an ongoing series focussing on new registrations in Australia, Research Review has released a product review of the use of beclometasone dipropionate/formoterol (Fostair) for patients with asthma.

This review discusses the evidence in support of the use of Fostair, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials. It also provides commentary and recommendations from Professor Francis Thien, Director of the Department of Respiratory and Sleep Medicine at Box Hill Hospital, Eastern Health, and the Monash University Clinical School in Melbourne, Australia.

 

ASCOT trial

ASCOT is a clinical trial that will generate clinical evidence about treatment for COVID-19 that can be applied during the pandemic to reduce mortality or the need for mechanical ventilation in hospitalised but not yet critically ill patients with COVID-19.

The trial is conducted on an adaptive platform, results will be continually analysed, so that ineffective therapies can be stopped and new therapies can be evaluated as part of the trial. The trial will be conducted across more than 60 sites in Australia, New Zealand and Asia. The trial is registered at: ACTRN12620000445976, Ethics approval granted through Melbourne Health Human Research Ethics Committee HREC/62646/MH-2020.097

Potential Treatments for COVID-19

There are currently no specific therapies for COVID-19. The two main strategies are to limit the virus replicating (antiviral therapies) or to modulate the immune response (in some severe cases, there is a damaging over exuberant immune response).

ASCOT intends to randomise patients to different therapies to understand their impact on clinical outcomes. We will do this for existing therapies, but also be set-up to test new and emerging therapies as they become available.

ASCOT Trial Intervention

Initially, an open label trial of two existing treatments in a 2×2 factorial design with usual care arm will be conducted.

  1. Lopinavir/ritonavir (kaletra), a combination medicine that is used to treat human immunodeficiency virus-1 (HIV-1) infection
  1. Hydroxychloroquine, a medicine used to treat rheumatoid arthritis and other inflammatory conditions and to prevent and treat malaria.

Protocol documents and further details are available at www.ascot-trial.edu.au

 

Can you help TSANZ make a difference?

Your support makes a difference, and helps us continue to provide funding for research and our TSANZ awards. If you would like to support our work, you can leave a tax deductible donation of your choice in our areas of need.

1. Making a donation to our Benevolent Fund

The Benevolent Fund supports projects aimed at improving the respiratory health care of individuals who are in a setting where health care resources and delivery are poor.
CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

2. Making a donation to support research

With your support, we can continue to support Australia and New Zealand’s most significant and cutting edge respiratory health research, and benefit Australians and New Zealanders suffering from lung disease.
Please CLICK HERE to make a donation or by filling out the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au.

3. Establishing a named award

For significant donations of above $10,000 AUD, a TSANZ award can be established in your name. Please call the TSANZ office on +61 2 9222 6200.

4. Leave TSANZ a gift in your will

If you are interested in supporting TSANZ in the future, one way to do so is to leave TSANZ a gift in your will. Any support is greatly appreciated and will leave a lasting legacy.
If interested, please notify us by ticking the box on the Support TSANZ form. Once you have completed the form, please email TSANZOffice@thoracic.org.au. Alternatively, please call the TSANZ Office on +61 2 9222 6200.

5. TSANZ New Zealand Branch Incorporated 

New Zealand members are reminded that you are also able to make a tax deductible donation directly to the NZ branch. You can assist the NZ branch to provide services to members across NZ. If you make a payment via electronic funds transfer (EFT), please notify the TSANZ office so that we can arrange a receipt.
CLICK HERE to make a donation.

Thank you for your continued support of TSANZ.

 

VOLUME 6.02 – FEBRUARY 2021

VOLUME 4.02 APRIL 2019

Research Roundup:

April 2019

.
 

Welcome Message

The TSANZSRS19 was a great success and we thank all delegates and exhibitors for supporting respiratory research and professional development once again.

At TSANZSRS19 respiratory research received a much needed boost of funding from TSANZ, LFA, CFA, NAC, and our partners. These awards were announced at the Respiratory Research Excellence Awards session and the Gala Dinner. Please find a re-cap of all the Thoracic Society Board Awards and Research Awards below, including the winners of the Special Interest Group Awards.

During the conference we opened a number of larger TSANZ awards, namely the AstraZeneca Respiratory Research Fellowships, which will support one early-career researcher and one mid-career researcher and the Vertex Cystic Fibrosis Research Awards, which will support one adult CF research project and one paediatric CF research project. There are also opportunities for IPF PhD scholarships and Menarini travel awards from the Lung Foundation. Links to these awards can be found in the Open Awards section below.

Enjoy the April edition of your research roundup.

Prof Sandra Hodge

Chair, Research Sub-Committee

$1 MILLION FOR LUNG DISEASE RESEARCH ANNOUNCED

Top lung health bodies raise much needed funds but more investment needed

(Thursday, 8th April 2019): Over a million dollars in lung research investment was announced over the weekend at the Respiratory Research Excellence Awards at the Australia and New Zealand Annual Scientific Meeting for Leaders in Lung Health & Respiratory Science(TSANZSRS19) on the Gold Coast. The conference brings together Australia and New Zealand’s leading lung health experts to present latest research and improve knowledge and understanding of lung disease.

The Research Excellence Awards, run for the second year by Thoracic Society of Australia and New Zealand (TSANZ) – the hosts of the conference – alongside the Lung Foundation, Cystic Fibrosis Australia and the National Asthma Council of Australia, provides over 40 researchers with support in the form of project funding, fellowships and travel grants raised through private donations, sponsorship and leveraged financing from recipients’ institutions.

“We’re honoured to be able to support some of Australia’s greatest minds in lung disease research; research that’s making a difference to the lives of the 1 in 4 Australians with lung disease,” said TSANZ President Elect Professor Bruce Thompson.

“This funding enables our researchers to build respiratory knowledge and capacity in the respiratory workforce, with the overall goal of preventing, curing and alleviating disability from lung disease. Every dollar invested takes us one step closer to reaching that goal,” he said.

Despite the success of the Awards, the organisers warn that lung disease research is still grossly underfunded when compared to other diseases. Far more investment is required, they say.

“It’s important to recognise the exceedingly hard work that our organisations are putting in to raising the profile of respiratory research, and to express our thanks for the contribution of donors, sponsors and institutions This is only our second year and look at what we’ve achieved,” said TSANZ CEO Tanya Buchanan.

“However, fundraising alone is not the way to manage diseases affecting a quarter of Australians. Lung disease has to attract the same level of research funding enjoyed by other disease areas such as breast, prostate, and heart disease. We look forward to seeing if the implementation of the National Strategic Action Plan for Lung Conditions delivers this,” she said.

2019 RESPIRATORY RESEARCH EXCELLENCE AWARD WINNERS

TSANZ would like to congratulate the following Award winners. For information on how to apply for next year’s Awards visit the TSANZ website Research and Awards page.

Society Medal

Professor Helen Reddel

Research Medal

Professor Philip Hansbro

Laennec Medal

Professor Allan R Glanville

Ann Woolcock New Investigator Award

Jesse Armitage

Best training Video

Elizabeth Salamon, Selena West, Ursula Swan, Sandra Daly

CSL Behring TSANZ / LFA Alpha-1 Anti-trypsin Deficiency Research Award

Gang Liu

Australian Cystic Fibrosis Research Trust Innovation Grant

Gerard Kaiko, Peter Wark, Shafagh Water, and Adam Jaffe

TSANZ and National Asthma Council Australia Asthma and Airways Career Development Fellowship

Kimberly Wang

Boehringer Ingelheim COPD Research Award 2019

Tatt Jhong Haw

Maurice Blackburn Grant-in-Aid for Occupational Lung Disease

Jane Bourke and Ryan Hoy

Boston Scientific Research Award for Interventional Pulmonology

Sanjeevan Muruganandan

Vertex Cystic Fibrosis Research Awards

ECFS: Elena Schneider-Futschik

NACFC: Rebecca Stockwell

TSANZ Peter Phelan Research Award

Elena Schneider-Futschik

TSANZ Rob Pierce Grant-In-Aid for Indigenous Lung Health

Gabrielle McCallum

TSANZ / Boehringer Ingelheim Australia COPD Travel Award

Alen Faiz

TSANZ / Boehringer Ingelheim New Zealand COPD Travel Award

Eskandarain Shafuddin

TSANZ/JRS Early Career Development Award

Jemma Seyfang

Janet Elder International Travel Awards

Mid-Career Award Recipient: Kimberley Wang

Early Career Award Recipient 1: Vikas Goyal

Early Career Award Recipient 2: Yet H Khor

TSANZ Respiratory Nurse Career Development Award for Indigenous Research

Betty Poot

Christine Sullivan

Maurice Blackburn ASM Travel Award

Leona Dowman

Shine a light a lung cancer PhD 2019

Kanishka Rangamuwa

David Wilson PhD Scholarship in Idiopathic Pulmonary Fibrosis Research 2019

Archana Gaikwad

Shine a light on lung cancer grant-in-aid

Surein Arulananda

Lung Foundation Australia/ Eleanor Greenwood Memorial Grant in Aid for Interstitial Lung Disease Research

Yet Hong Khor

Lung Foundation Australia /Lizotte Family Research Award for Interstitial PF Research

Leona Dowman

Lung Foundation Australia /Ludwig Engel GIA for Physiological research

Katrina Tonga

Lung Foundation Australia /Ivan Cash Research GIA – IPF

Adelle Jee

Lung Foundation Australia /Cochrane

Jenifer Liang

Shine a light on lung cancer nursing/allied health fellowship in lung cancer research

Vanessa Brunelli

Lung Foundation Australia Travel Awards: Menarini Travel Grants

ERS – Hannah O’Farrell and Jack Bozier

ATS – Thomas Altree and Razia Zakarya

APSR – Leanne Ross and Hai Bac Tran

Lung Foundation Australia/Eleanor Greenwood Memorial ILD Travel Grant

Cecilia Prele

Michael Schuliga

Jade Jaffar

 

SIG AWARDS

Supported by TSANZ

Cell, Immunology and Molecular Biology: Dhammika Leshan

Evidence-based Medicine and Practice: Yet Hong Khor

Peter van Asperen Paediatric: Kiara Sclip

Physiotherapy: Jamie Wood

Respiratory Infectious Disease: Benjamin Diggins

Tobacco: Henry Gomez

Supported by Asthma Australia

Asthma & Allergy: Teresa Williams

Supported by National Asthma Council

Asthma & Allergy : Cherry Thompson

Supported by Lung Foundation Australia

Pulmonary Physiology and Sleep, John Reid Prize: Graeme Zosky

David Serisier Memorial Award for Translational Research in Bronchiectasis: Su Wei Khung

Supported by Cystic Fibrosis Australia

Cystic Fibrosis: Elena Schneider-Futschik

Supported by Maurice Blackburn

Lung Cancer: Lara Edbrooke

Occ Env Lung Disease / Population Health: Edward Harris

Palliative Care and Symptom Support: Thomas Moran

Supported by Carroll & O’Dea

Interventional Pulmonology and Bronchoscopy: Deirdre Fitzgerald

Supported by Boehringer Ingelheim

Orphan Lung Diseases, Lung Transplant, Interstitial Lung Disease and Pulmonary Vascular Disease: Jemma Seyfang

Primary Care: Mary Roberts

Chronic Obstructive Pulmonary Disease: Sonia Cheng

Respiratory Nurses: Jane Neil

TSANZ Best Poster: Kris Nilsen: A new tool to monitor disease in IPF

CONGRATULATIONS TO…

TSANZ would also like to take this opportunity to congratulate the following New Fellows for 2019:

  • Prof Anne Holland
  • Dr Denise O’Driscoll
  • Dr Jane Bourke
  • A/Prof Jeff Garrett
  • Prof Paul Foster
  • Prof Peter Eastwood
  • Prof Sandra Hodge

 

Open Awards

Thoracic Society Awards

AstraZeneca Respiratory Research Fellowships – closes 2nd June 2019

Vertex Adult Cystic Fibrosis Research Award – closes 2nd June 2019

Vertex Paediatric Cystic Fibrosis Research Award – closes 2nd June 2019

Lung Foundation Awards

Lung Foundation Australia Brian Eaton Memorial PhD Scholarship in IPF – closes 10th June 2019

Lung Foundation Australia Diana Cox PhD Scholarship in IPF – closes 10th June 2019

Lung Foundation Australia / A Menarini Pty Ltd 2019 Travel Awards 

Travel application deadlines

ATS: 22nd March 2019 (5pm AEST)

ERS: 31st July 2019 (5pm AEST)

APSR: 13th September 2019 (5pm AEST)

 

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Watch this space for more award announcements…

Respirology – Editor’s Choice

Respirology Issue 24.4 2019

Implications of the diagnostic criteria of idiopathic pulmonary fibrosis in clinical practice: Analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

Helen E. Jo, Ian Glaspole, Nicole Goh, Peter M.A. Hopkins, Yuben Moodley, Paul N. Reynolds, Sally Chapman, Eugene Haydn Walters, Christopher Zappala, Heather Allan, Sacha Macansh, Christopher Grainge, Gregory J. Keir, Andrew Hayen, Douglas Henderson, Sonja Klebe, Stefan B. Heinze, Anne Miller, Hannah C. Rouse, Edwina Duhig, Wendy A. Cooper, Annabelle M. Mahar, Samantha Ellis, Samuel R. McCormack, Bernard Ng, David B. Godbolt, Tamera J. Corte

DOI: 10.1111/resp.13427 

Distribution of participants in the Australian IPF Registry

 

A consensus opinion amongst stakeholders as to benefits of obstructive sleep apnoea treatment for cardiovascular health

Shane A. Landry, Siobhan Banks, Peter A. Cistulli, Garun S. Hamilton, Laure Héraud, Kristina Kairaitis, Steven Lubke, Sutapa Mukherjee, Teanau Roebuck, Joesph Soda, Darren Umbers, Shantha M. W. Rajaratnam, Darren Mansfield.

DOI: 10.1111/resp.13413

 

From left to right: Prof Shantha Rajaratnam, Dr Shane Landry, A/Prof Darren Mansfield from Monash University and the Monash Medical Centre in Melbourne, Australia

Research Project and Survey Requests

Current Opinions of Severe Asthma Specialists on the Utility of Biomarkers for the Management of Corticosteroid Treatment: A Survey

If you are an Australian clinician involved in the care of patients with severe asthma, we would be very grateful if you could complete a brief questionnaire.

We would ideally like to sample opinions from specialists involved in the care and management of patients with severe asthma to reach consensus. This is the second round of a multi-national Delphi process to reach a consensus and there may be follow-up questions based on the answers we receive from this round (with likely 2-3 rounds in total).

A strategy to optimize corticosteroid use in the severe asthma population using biomarkers is currently being investigated. Professors Peter Wark and Jodie Simpson at the University of Newcastle, Australia are looking at an algorithm to adjust corticosteroid dose using exhaled nitric oxide (FeNO), and peripheral blood eosinophils. This survey is being conducted by them, and will also be part of a Masters by Research by Dr. James Michael Ramsahai. As part of this project, we would like to seek your views on some aspects of biomarker based corticosteroid adjustment in severe asthma.

For more details, please see the attached information statement. Please note that completion of the survey will imply consent to participate, and for the data collected to be used for analysis. You may withdraw at any time.

If you agree to participate, please follow the link to complete the survey

http://selectsurvey.hnehealth.nsw.gov.au/TakeSurvey.aspx?SurveyID=78M2nn61

*for issues with the survey link, please try copying and pasting into your browser and/or using Firefox browser. Feel free to contact the investigators with any questions*

Thank you,

Peter Wark
Jodie Simpson
J. Michael Ramsahai
 JamesMichael.Ramsahai@uon.edu.au

 

Survey of Attitudes of Australian Specialists to Lung Cancer Screening with Low Dose Computed Tomography

To Members of the Thoracic Society of Australia and New Zealand,

Lung cancer screening with low dose computed tomography has been implemented overseas however is still a debated topic within Australia. We are conducting a survey of Australian specialists and their knowledge and attitudes towards lung cancer screening and perceived barriers to the implementation of lung cancer screening with low dose computed tomography within Australia.

The anonymous survey is available online using the SurveyMonkey survey tool and takes approximately 7 minutes to complete.  It can be accessed via the following link.  https://www.surveymonkey.com/r/AttitudesToLDCT

Please don’t hesitate to contact us if you require any further information.  We attach our study protocol and copy of HREC approval (The Prince Charles Hospital Human Research and Ethics Committee LNR/2018/QPCH/44970).

Thank you for your kind support.

Yours truly

Rachel McLellan, Advanced RACP Trainee
Kwun Fong
Henry Marshall
Rayleen Bowman
Ian Yang

University of Queensland Thoracic Research Centre at The Prince Charles Hospital
Metro North Hospital and Health Service | Queensland Government
Rode Road, Chermside, Brisbane QLD 4032, AUSTRALIA
t. 61 7 [31394000] e. ILST@health.qld.gov.au | www.health.qld.gov.au

 

 

New survey about Victorian doctors’ end-of-life decision-making

Victorian doctors in specialties likely to be involved in end-of-life decisions are being surveyed about their decision-making practices involving adult patients. Researchers from the NHMRC-funded Centre of Research Excellence in End-of-Life Care are conducting a study to determine what sort of end-of-life decisions are being made by doctors, how often these decisions occur and for what sort of patients.

At present, there are no up-to-date, representative Australian data describing the frequency and nature of medical end-of-life decisions involving adults, and the characteristics of patients about whom such decisions are made. The research aims to provide an evidence base to understand current medical practice in Victoria including the extent to which palliative care is provided to patients at the end of life. Findings from this research will also inform improvements in the quality of end-of-life care.

A sample of Victorian doctors will be contacted in April and May by the AMA’s Australia Medical Publishing Company (AMPCo) to invite them to complete a survey.  The survey can be completed in hard copy or online.  Participating doctors who complete their survey before 16 May will go into the draw for one of three prizes to the value $100, in fine wine, or a donation to a registered charity of your choice.

If you have any queries about this research, please feel free to contact Dr Rachel Feeney[rachel.feeney@qut.edu.au]. The research team is grateful for the time and insight of the doctors who support this research by completing this survey.

 

Management of complicated parapneumonic effusions and empyemas with the use of intrapleural fibrinolytics

Dear TSANZ Member,

You are invited to participate in a survey that is being conducted as part of a research study. The following survey asks a series of questions about your current practice, specifically with regards to the management of complicated parapneumonic effusions and empyemas with the use of intrapleural fibrinolytics. Insights gained will be considered for future presentation and publication. The estimated time to complete the survey is 10 minutes. Partial responses will not be saved if you exit out the survey early. Your participation is voluntary and anonymous. Responses will be kept confidential. Your contribution is greatly appreciated.

The survey can be completed here: https://hms.az1.qualtrics.com/jfe/form/SV_8ddQsXRFwaqAtPD

If you have any questions about the survey, please contact the study team at: vholden@som.umaryland.edu

We thank you in advance for your participation.

Sincerely,

Van Holden, MD
Mihir Parikh, MD
Alex Chee, MD
Adnan Majid, MD

Division of Thoracic Surgery & Interventional Pulmonology
Beth Israel Deaconess Medical Center
Harvard Medical School

The attached survey has been approved by the Beth Israel Deaconess Institutional Review Board – The IRB Protocol # is 2018P000052.

 
 

.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 2.10 DECEMBER 2017

Research Roundup:

December  2017

.
 

Welcome Message

We have some good news for respiratory researchers. After much discussion with the NHMRC, the Field of Research classification “Cardiovascular Medicine and Haematology” has now been updated to include ‘respiratory’. From now on the FoR should read “Cardiorespiratory Medicine and Haematology”. TSANZ thanks the NHMRC for responding to our concerns and we are pleased to see Respiratory now recognised in this heading.

On behalf of the Australian Cystic Fibrosis Research Trust and Cystic Fibrosis Australia, we am pleased to announce that the Australian Cystic Fibrosis Research Trust 2018 Innovation Grant is now open. The purpose of the Innovation Award is to allow a CF researcher to explore novel concepts at the initial feasibility stage. This grant was highly competitive and popular last year. Innovative applications on any aspect of CF are welcome, even those lacking pilot data. 

We also welcome the LFA Bill van Nierop PhD Scholarship in Idiopathic Pulmonary Fibrosis Research 2018, a collaborative initiative of Lung Foundation Australia, Thoracic Society of Australia & Centre for Research Excellence in Pulmonary Fibrosis. This PhD scholarship invites university partnership and will help build workforce capacity in IPF research.

Lastly, the TSANZ AstraZeneca Respiratory Research Fellowship remains open for application for early-career and mid-career researchers in the asthma/and or COPD fields of research.

This is the twentieth edition of the research roundup and as we enter into the festive season we would like to thank you for your engagement and research, and remind you of two things:

1) Stay safe this Summer and look after your close ones.

2) We have a few awards open over the Summer, so please take a look, and if these awards are for you, we wish you all the best in your preparation.

If you have any content which you feel fits the theme please feel free to send it into the TSANZ Office. Also remember, we have the Holy Grail showcase available if you would like to share your story.

Wishing you a wonderful break and enjoy the December edition of your research roundup.

Prof Phil Hansbro

Prof Sandra Hodge

Co-Chairs, Research Sub-Committee

Open Awards

TSANZ Research and Career Development Awards

TSANZ / AstraZeneca Respiratory Research Fellowship – closing 19th January 2018

TSANZ Indigenous Respiratory Nursing Award – closing 21 January 2018

For more information visit https://www.thoracic.org.au/researchawards/tsanz-awards

Cystic Fibrosis Australia Awards

Australian Cystic Fibrosis Research Trust 2018 Innovation Grant – closing 29 January 2018

Lung Foundation Australia Awards

The Lung Foundation Australia Bill van Nierop PhD Scholarship in Idiopathic Pulmonary Fibrosis Research 2018 – closing 19 January 2018

How to participate

Follow the links above to access each award application form and download the information sheet.

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Watch this space for more award announcements…

 

TSANZ 50th Anniversary Benevolent Grant

The Thoracic Society of Australia and New Zealand Ltd (TSANZ) Ltd became a Health Promotion Charity in 2011. With this, the 50th Anniversary TSANZ Benevolent Grant was established to help TSANZ contribute to worthwhile causes intended to improve respiratory health care delivery within Australia and New Zealand, and internationally. There is opportunity to raise funds for such special projects by receiving donations from TSANZ members. 

Thanks to the generosity of TSANZ donors, the organisation is now able to make available two award categories to support philanthropic activities aimed at improving respiratory health care. This is not a research program. Funding must be used for philanthropic activities to improve respiratory health care in settings where resources and delivery are poor. For example, the purchase of equipment, the implementation of training for health care professionals or patients, or direct patient programs would qualify for this funding.

Visit the TSANZ 50th Anniversary Benevolent Grant online!

There are two award categories:

  • People’s Choice Award valued at up to $10,000 AUD
  • Directors Choice Award valued at up to $10,000 AUD

There is up to $10,000 funding available for each category which may be provided to one or multiple awards. TSANZ reserves the right to not issue any funding. 

Winners will be announced at the TSANZSRS ASM in Adelaide, 2018.

 

Respirology Issue 23.1 – Editor’s Choice

Effect on health-related quality of life of ongoing feedback during a 12-month maintenance walking programme in patients with COPD: A randomized controlled trial

Sally L. Wootton, Zoe McKeough, Cindy L.W. Ng, Sue Jenkins, Kylie Hill, Peter R. Eastwood, David Hillman, Christine Jenkins, Nola Cecins, Lissa Spencer, Jennifer Alison

DOI: 10.1111/resp.13128

 

Walking tracks used by participants with COPD who completed an 8-10 week supervised, ground-based walking training program before starting the maintenance study

 

Usefulness of a routine endoscopic assessment of laryngeal lesions after lung cancer surgery

lex Fourdrain, Florence De Dominicis, Jules Iquille, Sophie Lafitte, Geoni Merlusca, Alejandro Witte Pfister, Patrick Bagan, Pascal Berna

DOI: 10.1111/resp.13139

 

Grant Bulletin

This grant bulletin contains direct-to-researcher grants and awards:

Allen Foundation Grants (2018) – closes 31/12/17
Priorities are: to fund relevant nutritional research; to support programs for the education and training of mothers during pregnancy and after the birth of their children; to assist in the training of persons to work as educators and demonstrators of good nutritional practices; to encourage the dissemination of information regarding healthful nutritional practices and habits; in limited situations to make grants to help solve immediate emergency hunger and malnutrition problems.

Hargreave Research Fellowship – closes 31/01/2018
A position is available for a one-year Fellowship named for Dr. Frederick (Freddy) Hargreave, a pioneer in the field of asthma and pulmonary medicine and a dearly missed colleague. The position will be based at the Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and affiliated with McMaster University. There is potential for renewal for a second year.

NSW Health and Medical Research Sponsorship Program – closes 12/01/2018
Collaboration and sharing of knowledge and new ideas across the health and medical research sector through conferences, events and forums is important for capacity building and for promotion of excellence in health and medical research in NSW. To support this collaboration, the Office for Health and Medical Research is offering sponsorship grants up to $20,000 for eligible conferences or events in NSW. Funding is available on a competitive basis with a total Program funding pool of $100,000. The Program is designed to support medical research institutes, peak and professional bodies, not-for-profits and non-government organisations who may not have access to other sources of sponsorship funding.

ALTA Alpha-1-Antitrypsin Laurell’s Training Award – letter of intent submission closes 01/03/2018
A primary goal of the Alpha-1-Antitrypsin Laurell’s Training Award (ALTA) is to identify and engage investigators (both physicians and scientists) who are early in their careers in a longstanding commitment to investigating alpha-1-antitrypsin deficiency (AATD). In awarding 2 grants, the goal/intention is to award one grant for a clinical proposal and a second for a basic research proposal. Another objective of the ALTA award is to strengthen the network between scientists and clinicians working in the field of AATD, facilitating the collaboration between research institutions.

Rolling Grants

John Templeton Foundation
Interest areas are: science and the big questions; character virtue development; freedom and free enterprise; exceptional cognitive talent and genius; genetics; voluntary family planning.

Boehringer Ingelheim Fonds Travel Grants
Grants for non-European researchers to travel to Europe for up to three months to pursue an experimental project in basic biomedical research.

Baxalta Bioscience Grants – Medical Education & Fellowship Grants
Baxalta provides Medical Education & Fellowship Grants to support accredited or unaccredited educational symposia, seminars, web-based sessions, or fellowship programs directed at certified healthcare professionals. They are currently interested in supporting the following areas: Immunology; Hematology; Oncology.

The Balnaves Foundation
The Balnaves Foundation supports organisations that aim to create a better Australia through education, medicine and the arts with a focus on young people, the disadvantaged, and Indigenous communities.

Availability of CF rats and organs/tissues in Australia – Expressions of Interest

The CF research community in Australia now has access to two colonies of CF rats, as well as the potential for accessing tissue samples for research purposes. 

Using CRISPR/Cas9 gene editing the CF Airway Research Group (CFARG) in Adelaide, in collaboration with the Australian Phenome Network (APN), has developed and bred two CF rat colonies during 2016-7 that we expect to gradually become available to other Australasian groups for their CF research.  The creation and the operation of the colonies was supported by APN and CF South Australia.

We are currently only starting to characterise the lung disease in the two models – one is a Phedel508 mutation, and the other a CFTR knockout.  Though our plan is to first devote the CF animals to our own CF research needs, we intend the production of the two colonies to also be able to provide CF rats and tissues samples to other CF researchers in our region.

We already have limited amounts of preserved and frozen organ samples from both types of CF rats, and we expect to be able to provide materials /animals on a fee basis (yet to be determined) or via collaborative research arrangements.  As we have not current interest or expertise in non-lung CF organ issues, we are keen to ensure that other who do have those interests can take advantage of the available tissues for their own CF research.

We also are happy to provide access to samples and animals to New Zealand but we do not know the biosecurity implications, if any.

If you have a general or specific interest in obtaining CF rats or CF rat tissues we invite you to register your interest with us.  We will then make contact to determine specific needs, desired method of interaction, likely timelines for supply, and so on. 

Please fill out the basic details below and return by email to: david.parsons@adelaide.edu.au   with heading “CF rat Expression of interest”

---------------------------------------------------------------------------------------
Name:

Email:

Research Group:

Phone: Location:

My interests (circle or highlight those required):

CF rats
Littermate Hets / WT
Lung samples (CF / Het / WT)
Non-lung samples (CF / Het / WT)

How soon do you want the above?

Now
<6 months
<12 months
Future, sometime…

Assoc Prof David Parsons
CFARG, Adelaide, Sth Australia
Mob: 0404 853173 email: david.parsons@adelaide.edu.au

Are you a Severe Asthma Physician?

Dear TSANZ Members,

We are currently conducting a survey of  Australian clinicians involved in the care of patients with severe asthma, and are seeking your opinions on the Utility of Biomarkers for the Management of Corticosteroid Treatment. This is the first round of a Delphi process to reach a consensus and there will be follow-up questions based on the answers we receive from round one.

Professor Peter Wark and I at the University of Newcastle, Australia are looking at an algorithm to adjust corticosteroid dose using exhaled nitric oxide (FeNO), and peripheral blood eosinophils. This survey is being conducted in conjunction with this project, and understanding the current sentiment on the use of biomarkers in this patient population is crucial to furthering the future development and implementation of biomarkers, and the treatable trait approach in general. In addition, this is being done as a larger international effort to gauge opinions on the use of biomarkers across Europe and Australia.

If you are currently involved in the management of patients with severe asthma, we would sincerely appreciate if you could take the time to complete the survey (link below) that has been sent out as part of the Asthma SIG this week.

https://selectsurvey.hnehealth.nsw.gov.au/TakeSurvey.aspx?SurveyID=l6M2m5m3#

Thank you,

Prof Jodie Simpson

Research Project and Survey Requests

‘Usual’ antenatal asthma management

Our research team at the Hunter Medical Research Institute (HMRI) and University of Newcastle is conducting a nationwide survey to determine what ‘usual’ antenatal asthma management consists of. Gaining this knowledge will help to form a foundation on which to build improved antenatal asthma management across Australia.

If you are a health professional who provides antenatal care within Australia then we invite you to participate in a survey. This survey should take approximately 10 minutes to complete.

Ethics approval has been granted for this study (NSW HREC Reference No: HREC/16/HNE/394).  All responses will be anonymous and confidential. Further information about the project and request for consent is outlined once you click on the survey link. If you have any questions regarding this research, please do not hesitate to contact Vanessa Murphy at Vanessa.Murphy@newcastle.edu.au or Karen McLaughlin on 0425277200.

Please click on the link below to proceed to the survey. If the link fails to load automatically, please cut and paste it into your internet browser:

https://redcap.hmri.org.au/surveys/?s=NR78PWYW49

Thank you,

Dr Vanessa Murphy, Vanessa.Murphy@newcastle.edu.au
Ms Karen McLaughlin, Karen.McLaughlin@hnehealth.nsw.gov.au

 

 

 
 
 
 
 
 
 
 
 

.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 2.6 AUGUST 2017

Research Roundup:

August  2017

.
 

Welcome Message

Have you heard? Abstracts for TSANZSRS 2018 are now open. With this, our abstract-linked awards are also open. We are once again calling for applicants for the Ann Woolcock New Investigator Award, the JRS Travel Award, the Janet Elder Travel Award, and the Boehringer Ingelheim COPD Travel Award – which is now available to support travel to a range of international respiratory conferences (instead of only CHEST). Our ASM Travel awards are also open and we hope that everyone who is eligible takes up these opportunities.

More details on these awards are below and online.

Just over the horizon is APSR 2017 in Sydney.  A large number of abstracts have been received and late breaking abstracts will open on August 9th. Abstract acceptance will be notified in mid- August. If your abstract is accepted, you must be registered by September 28th. The developing program is now live. The theme is Lung Health in a Changing Worldand with a diverse and experienced group of international speakers attending, this should be a highly educational and engaging meeting. Early bird registration closes 3 September.

We have been able to partner with TEVA Pharmaceuticals and launch the TSANZ/TEVA Scholar Awards which cover registration costs for APSR 2017. These are open to Advanced Trainees in Respiratory and/or Sleep medicine and applications close on the 30th of August. Please spread the word – there are 30 scholarships available.

I would also like to update you on the consultation on A framework for NHMRC assessment and finding of clinical trials and cohort studies which we recently responded to. Thank you to those who assisted with this. Our response was in line with our commitment to increasing investment in respiratory research. While TSANZ was broadly supportive of the consultation recommendations, we advocated for inclusion of a policy review period, a moderation of process, opportunity to appeal and some consideration of a change in the length of the application given the necessity to include other supporting documentation for specific types of studies.

We will continue to work to increase funding for respiratory research and will adapt as the research landscape in Australia and New Zealand continues to change.

Lastly, there are a number of surveys at the end of this email and I urge you to participate in these and help where you can.

Enjoy the August edition of your research roundup.

Prof Phil Hansbro

Chair, Research Sub-Committee

 

The following articles will take you to thelimbic.com

Work-related lung disease cases “tip of the iceberg”. A national register to record every case of work-related lung disease is one step closer following lobbying from the TSANZ and the Lung Foundation. Read More.

 + The rules for work-related lung disease compo are “unfair”. There are calls to expand the list of work-related lung disorders eligible for government compensation in NSW, amid concerns many with life-threatening conditions are missing out. Read More.

Oxygen saturation should be the 5th vital sign. A pulse oximeter should be as ubiquitous as a stethoscope, according to the British Thoracic Society’s new guidelines. Read More.

Non-invasive ventilation cuts COPD readmissions. Hard to treat patients with frequent COPD exacerbations can be kept out of hospital for longer when NIV is added to home oxygen. Read More.

Chronic breathlessness syndrome: a new name without shame.  We speak to Palliative medicine specialist Professor David Currow about his mission to get chronic breathlessness recognised as a distinct clinical entity. Read More.

Turf war stalling antibiotic stewardship. A rift between respiratory physicians and infectious diseases specialists could be stalling efforts to fight the growing problem of antimicrobial resistance in patients with respiratory infections, researchers claim. Read More.

Better bedside management of pleural effusions. Brisbane doctors have significantly improved the outcomes of patients with pleural effusions by giving registrars and trainees practical hands on training on the use of pleural ultrasound. Read More.

Open Awards

Thoracic Society Awards

TSANZ / TEVA Scholar Award

Encouraging all TSANZ Advanced Trainees Members to attend APSR 2017 for career development. Close 30 August 2017.

Abstract-linked awards are now open

Ann Woolcock New Investigator Award

The Ann Woolcock New Investigator Award is presented at the TSANZ Annual Scientific Meeting (ASM) to acknowledge excellence in the conduct and presentation of scientific research. 

This is a Travelling Fellowship of AUD$1500 plus expenses (return economy airfare, meeting registration and accommodation) to support the recipient to attend and present their original high-quality research to the next Annual Scientific Meeting of the Asia-Pacific Society of Respirology (APSR). Finalists (excluding the winning applicant) will receive a certificate of achievement and AUD $500.

This award furthers one of Professor Ann Woolcock’s goals of fostering research ties between the TSANZ and the APSR.

To apply for the Ann Woolcock New Investigator Award, you must complete the application coversheet using the upload functionality in the online abstract submission portal. To view the Ann Woolcock New Investigator Award eligibility criteria and application here coversheet please click here.

Boehringer Ingelheim COPD Travel Award

This travel award is designed to reward, encourage and provide international exposure for Advanced Trainees in Respiratory Medicine, junior Respiratory Physicians, post-doctoral respiratory healthcare professionals, and Respiratory Researchers whose work focuses on chronic obstructive pulmonary disease (COPD).

The award consists of up to AU$4000 to cover the recipient’s expenses (return airfare, registration, accommodation, living expenses) to attend and present an abstract at a relevant international respiratory conference, including: the American College of Chest Physicians, the European Respiratory Society, Asian Pacific Society of Respirology , or the American Thoracic Society.

To view the Boehringer Ingelheim COPD Travel Award eligibility criteria and application coversheet please click here.

Janet Elder International Travel Award

These awards will be made to three respiratory scientists or clinicians on the basis of scientific merit of their submitted abstract to the 2018 TSANZ Annual Scientific Meeting (ASM) to support their professional development in respiratory research. There will be two awards for early career researchers and one award for a mid-career researcher.

Each award consists of AUD$2500 to contribute to expenses to attend and present an abstract at an international scientific meeting of the recipient’s choice within the following year. 

These awards are made in the memory of Dr Janet Elder, one of the pioneers of respiratory medicine in Western Australia.

To apply for the  Award, you must complete the application coversheet using the upload functionality in the online abstract submission portal. To view the Janet Elder International Travel Award eligibility criteria and application coversheet please click here.

Japanese Respiratory Society (JRS) Early Career Development

This Early Career Development Award is designed to reward, encourage and provide international exposure to promising recent advanced trainees/higher degree graduates. 

The award will cover the recipient’s expenses (return economy airfare to Japan, registration, accommodation, living expenses) to attend and present at the Annual Scientific Meeting of the Japanese Respiratory Society in the following year. This award is fully provided by the Japanese Respiratory Society.

To apply for the  Award, you must complete the application coversheet using the upload functionality in the online abstract submission portal. To view the Japanese Respiratory Society (JRS) Early Career Development eligibility criteria and application coversheet please click here.

TSANZ Travel Grants to 2018 ASM

These travel awards are made available to encourage eligible TSANZ members to attend and enrich the Annual Scientific Meeting (ASM) through presentation of their work and active participation in the meeting. They are awarded to eligible applicants planning to pursue a career in respiratory medicine or related fields, based on the quality of the abstract submitted for presentation to the ASM.

To be eligible for the TSANZ Travel Grants to 2018 ASM Award, you must submit an accompanying form of certification (attach here) completed by your supervisor/head of department using the upload functionality in the online abstract submission form. To apply for the  Award, you must complete the application coversheet using the upload functionality in the online abstract submission portal. To view the TSANZ Travel Grants to 2018 ASM eligibility criteria and application coversheet please click here.

Lung Foundation Australia Awards

Lung Foundation Australia and Boehringer Ingelheim Chronic Obstructive Pulmonary Disease Research Fellowship – 2018/2019

Valued at $80,000 per year/ one or two years

Lung Foundation Australia / Boehringer Ingelheim COPD Fellowship supports research to improve the diagnosis and management of Chronic Obstructive Pulmonary Disease in Australia. Specifically, the proposed research must be aimed at developing and/or delivering optimal care to people with COPD.

Relevant domains of research inquiry range from evaluation of population screening initiatives; interventions to improve diagnostic accuracy within primary care; through to issues of management in the context of a clinician-patient interaction to system level issues to do with the organisation, financing and performance of the health system, including COPD management of indigenous and ethnic minorities within Australia.

Lung Foundation Australia invites applications from medical and scientific graduates who will be a resident in Australia throughout the period of the research program. The Fellowship is available as either a one or two year award, with a value of $A80,000 per annum. The funds are to cover the salary (including on-costs) for the successful research fellow and for no other purpose.

Apply now


NEW Lung Foundation Australia and the Better Breathing Foundation Allied Health PhD Scholarship in Chronic Lung Disease – 2018/2021

Valued at $20,000 per year/four years: $40,000 per year/four years with matched funds

This Scholarship is made possible via a collaborative partnership with Lung Foundation Australia and the Better Breathing Foundation. The LFA/BBF Allied Health PhD Scholarship aims to support allied health professionals to undertake research into chronic lung disease. Relevant domains of research include any form of clinical, population, laboratory or genetics research.

Students with an allied health background wishing to undertake a PhD in chronic lung disease are invited to submit an application. This PhD Scholarship is aimed at a researcher who is commencing a higher degree and interested in improving outcomes for patients living with a chronic lung disease.

Lung Foundation Australia/Better Breathing Foundation will be allocating a set amount of funds of $20,000 per year over a four year period (total funding: $80,000) for the PhD Scholarship, with matching funds to be provided by the University.

Apply now


Lung Foundation Australia / Ivan Cash Research Grant-in-Aid for Idiopathic Pulmonary Fibrosis Research 2018

Valued at $5,000

The Ivan Cash Research Grant-in-Aid’s creation was made possible by a bequest from Mr Ivan Cash, who sadly died from his idiopathic pulmonary fibrosis (IPF) in 2008. Lung Foundation Australia invites applications for the Ivan Cash Research Grant-in-Aid valued at $5,000. This IPF Research Award is open to any individual health care professional or scientist, who will be required to collaborate with the Australian IPF Registry management committee to undertake and publish a specific focused analysis of part of the collected dataset of the Australian IPF Registry. The Australian IPF Registry management committee will provide support to the successful applicant to enable the completion of the required research.

Apply now


Lung Foundation Australia / Lizotte Family Research Award for Interstitial Pulmonary Fibrosis Research 2018

Valued at $5,000

Lung Foundation Australia invites applications for the Lizotte Family Research Award valued at $5,000 – to assist research in interstitial pulmonary fibrosis (IPF). This Research Award is open to any individual health care professional or group of health care professionals who are able to demonstrate an interest in IPF, including respiratory physicians, histopathologists, radiologists, researchers, registrars, trainees, nursing and allied health staff.

The funds may be used as a contribution towards IPF related research or pilot projects, or to fund travel or education with respect to increasing knowledge about IPF.

Apply now


Lung Foundation Australia / Ludwig Engel Grant-in-Aid for Physiological Research 2018

Valued at $5,000

Lung Foundation Australia invites applications for the Ludwig Engel Grant-in-Aid valued at $5,000 – to assist research in respiratory physiology. For the purpose of this Grant-in-Aid, Physiological Research is the use of any methodologies directed towards the elucidation of organ function and its understanding in a precise, quantitative manner.

The funds may be used as a contribution towards equipment, personnel or other running costs incurred in the conduct of research projects. The Grant-in-Aid is not to be used to fund conference travel or conference attendance.

Apply Now


Lung Foundation Australia / A Menarini Pty Ltd 2017 Travel Awards

Lung Foundation Australia and A Menarini Australia Pty Ltd are excited to announce that there will be six (6) Travel Grants of up to $3,000 for international conferences and up to $1,500 for national conferences on offer to key health professionals in Australia whose work is focused on improving outcomes for patients living with COPD.

Apply now


Lung Foundation Australia / A Menarini Pty Ltd 2017 Travel Awards

Lung Foundation Australia and A Menarini Australia Pty Ltd are excited to announce that there will be six (6) Travel Grants of up to $3,000 for international conferences and up to $1,500 for national conferences on offer to health professionals/researchers in Australia whose work is focused on improving outcomes for patients living with COPD.

How to participate

Follow the links above to access each award application form and download the information sheet.

More Information

Please email the TSANZ Awards Coordinator with any questions, comments or enquires.

Lung Foundation Australia contact details
Glenda Colburn | Phone 07 3251 3600 | Email: glenda@lungfoundation.com.au

Watch this space for more award announcements…

Lungs for Life Grant Bulletin

The Lungs for Life project has identified the following direct-to-researcher grants and awards due between late August and December, 2017:

Westpac Bicentennial Foundation Research Fellowship – closes 31/08/17
The Westpac Research Fellowship supports outstanding early career researchers whose ground-breaking work has the potential to make a difference in one of the Foundation’s focus areas: Technology and innovation, Strengthening Australia-Asia ties, and Enabling positive social change.

Westpac Bicentennial Foundation Social Change Fellowship – closes mid-August/2017
The Westpac Social Change Fellowship is an opportunity to invest in your capability, knowledge and networks with a view to helping you bring to life your innovative initiative for positive social change in Australia.

Rebecca L Cooper Medical Research Foundation – Medical Research Grants – closes 01/09/17
Advancing, promoting and encouraging medical research into Brain Sciences (psychiatry and neurology), Endocrinology and Diabetes, Geriatrics, Lung Disease (other than cancer), Rheumatology, Vision Sciences. Funding is primarily granted for the purchase of equipment, but may be used for other tangibles (e.g. therapeutic or imaging markers, software etc.). Funding requests for salaries/wages are not strongly supported, but will be considered by the directors.

The Prince Charles Hospital Foundation Emerging Researcher Grant – closes 01/09/17
The Emerging Researcher Grant is aimed at providing New Investigators who have previously received and successfully completed a New Investigator grant from TPCHF the opportunity to further develop their skills, experience and build the research capacity of TPCH The priority areas are: Heart disease – heart failure, valvular heart disease, congenital heart disease; Lung disease – lung cancer, asbestos related diseases, COPD, pulmonary hypertension, cystic fibrosis, sleep disorders, asthma; Dementia – Alzheimer’s disease, vascular dementia, Lewy Body disease, fronto-temporal dementia; Arthritis – osteoarthritis, joint replacement, growing cartilage.

Harkness Fellowships in Health Care Policy and Practice 2018-2019 – closes 05/09/17
For mid-career professionals (academic researchers, government policymakers, clinicians, managers, and journalists) from Australia, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland, and the United Kingdom, to spend up to 12 months in the US conducting a policy-oriented research study, working with leading US health policy experts, and gaining an in-depth knowledge of the US and other health care systems.

Tasmania Community Fund – small grants close 06/09/17, large grants close 27/09/17
To fund community organisations that make a difference by enhancing well-being and improving the social, environmental and economic outcomes for the Tasmanian community. Five category areas: children and young people; community participation and recreation; community well-being and life skills; connecting communities; culture, arts and heritage. Large grants are for applications for large infrastructure, asset and/or equipment.

Future Research Leader Fellowships – EOI closes 15/09/17
5 year full time Fellowships to provide salary and project support to encourage high calibre interstate and international emerging researchers to develop a program of work that support the activities that are being undertaken by the Translational Cancer Research Centres (TCRCs) in NSW. Applications must be in the area of implementation research and, more specifically, should address how research findings from the TCRCs can be taken up into routine cancer care.

CASS Medicine/Science Grants – 15/09/17
Research and development projects in science and/or medicine. Preference is given to proof of concept project applications. CASS will only accept applications from applicants employed by specific Victorian research centres.

Shepherd Foundation – closes 15/09/17
The Shepherd Foundation Trust welcomes grant applications from Victorian health professionals or research teams working in clinical, medical or scientific fields.  Grants are provided for research projects in all aspects of preventive medicine and/or occupational medicine. For research projects in all aspects of preventative medicine and/or occupational medicine. Applicants may apply for funding of one, two or three years.

Conquer Cancer Career Development Award – closes 21/09/17
Provides funding to clinical investigators who have received their initial faculty appointment to establish an independent clinical cancer research program. This research must have a patient-oriented focus, including a clinical research study and/or translational research involving human subjects. Submissions in all oncology sub specialties are welcome.

Financial Markets Foundation for Children – closes 30/09/17
Research programs designed to improve the health, welfare and wellbeing of Australian children. Preference will be given to projects focussed on children aged 14 years and under, although the Foundation will consider projects relating to children up to 18 years of age.

Cancer Research Institute CRI Irvington Postdoctoral Fellowship Program – closes 01/10/17
Supports qualified young scientists at leading universities and research centres around the world who wish to receive training in cancer immunology. An eligible project must be immunology with direct relevance to solving the cancer problem.

World Cancer Research Fund International – closes 06/10/17
To fund research studies exploring the link between diet, nutrition, body composition, physical activity, and cancer prevention and survival. There are 2 types of grants: Investigator Initiated Grants for Principal Investigators; and Pilot Grants to be used as start-up funds for pilot research. Two main themes: identifying the mechanisms that underpin the effects of diet, nutrition and physical activity on cancer; addressing the host factors that influence an individual’s susceptibility to cancer development or progression.

The Bonser Family Research Grant and Mi-tec Publishing Medical Research Grant – closes 21/10/17
Cancer Council Tasmania calling for research relating to the reduction of the incidence and impact of cancer on individuals and the community. It includes every aspect of care, from prevention and early detection that leads to a better outcome, treatment and supportive care. The priority area is cancer control.

Rolling Grants

Auswide Community Grants Scheme –  grants under $5 000 close 30/09/17, grants over $10 000 close 21/10/17, grants over$ 5 000 close 01/12/17.
Supports local activities, organisations, events and projects covering a wide range of sporting, cultural and community interests and endeavours. Includes community services, events and celebrations, buildings, public spaces and facilities, research, and organisational development.

John Templeton Foundation
Interest areas are: science and the big questions; character virtue development; freedom and free enterprise; exceptional cognitive talent and genius; genetics; voluntary family planning.

Boehringer Ingelheim Fonds Travel Grants
Grants for non-European researchers to travel to Europe for up to three months to pursue an experimental project in basic biomedical research.

Baxalta Bioscience Grants – Medical Education & Fellowship Grants
Baxalta provides Medical Education & Fellowship Grants to support accredited or unaccredited educational symposia, seminars, web-based sessions, or fellowship programs directed at certified healthcare professionals. They are currently interested in supporting the following areas: Immunology; Hematology; Oncology.

Coopers Brewery Foundation – current round closes 01/08/2017
Medical research and health care; educational development for the young; aged care; promotion of family and community support based on Christian values.

The Balnaves Foundation
The Balnaves Foundation supports organisations that aim to create a better Australia through education, medicine and the arts with a focus on young people, the disadvantaged, and Indigenous communities.

allport bequest – closes 30/06 and 31/12 yearly
Must benefit citizens of Hobart. Organisation must be charitable or the project must be for charitable purposes.

 

Respirology

New from ANZSRS

ANZSRS’s Spirometry Training Courses Position Statement
Maureen P. Swanney, Christopher A. O’Dea, Emily R. Ingram, Leanne T. Rodwell, Brigitte M. Borg, for the ANZSRS Spirometry Training Course Working Group

Respirology Issue 22.6

Is bronchial thermoplasty cost-effective as treatment for problematic asthma patients? Singapores perspective on a global model.

HAI V. NGUYEN , SAIDEEP BOSE, SHWETA MITAL, ANTHONY CHAU ANG YII, SHIN YUH ANG, SEAN SHAO WEI LAM, DEVANAND ANANTHAM, ERIC FINKELSTEIN and MARIKO SIYUE KOH

DOI: 10.1111/resp.13027

 

Cost-effectiveness acceptability curve of bronchial thermoplasty with and without optimized asthma therapy

Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions

JONATHAN A. GALLI , ALOKNATH PANDYA, MICHELLE VEGA-OLIVO, CHANDRA DASS, HUAQING ZHAO and GERARD J. CRINER

DOI: 10.1111/resp.13024

Research team at the Temple Lung Center in Philadelphia, USA. From left to right: Huaqing Zhao, Jonathan Galli, Chandra Dass, Michelle Olivo-Vega and Gerard Criner.  Not included in the photo is Aloknath Pandya.

Research Project and Survey Requests

Inhaler Overhaul in Sight for Mild Asthma  –  recruitment closing soon

Friends and family with mild asthma could soon have a new treatment at their fingertips if results of the Novel Start Study show the condition can be well managed without daily medication.

People with apparently mild asthma make up 20 per cent of adults who die of asthma, and a third of people who need emergency asthma treatment,” says asthma specialist Professor Helen Reddel, who is heading the study in Australia.

Asthma experts in New Zealand and at the Woolcock Institute of Medical Research in Sydney and John Hunter Hospital in Newcastle are testing a new combination puffer treatment that could reduce asthma flare-ups and change the way mild asthma is treated worldwide.

Anyone who is using only Ventolin (or similar) for their asthma can volunteer – recruitment closes soon – by the end of August 2017.

Woolcock Institute, Sydney, Australia
Call: 02 9114 0444 or email gloria.foxley@sydney.edu.au

Hunter Medical Research Institute, Newcastle, Australia
Call: 02 4042 0532 or email joanne.howes@newcastle.edu.au

Medical Research Institute of NZ – Wellington, NZ
Call: 04 805 0147 or email irene.braithwaite@mrinz.ac.nz

 

 

‘Usual’ antenatal asthma management

Dear Colleague,

Our research team at the Hunter Medical Research Institute (HMRI) and University of Newcastle is conducting a nationwide survey to determine what ‘usual’ antenatal asthma management consists of. Gaining this knowledge will help to form a foundation on which to build improved antenatal asthma management across Australia.

If you are a health professional who provides antenatal care within Australia then we invite you to participate in a survey. This survey should take approximately 10 minutes to complete.

Ethics approval has been granted for this study. All responses will be anonymous and confidential. Further information about the project and request for consent is outlined once you click on the survey link. If you have any questions regarding this research, please do not hesitate to contact Vanessa Murphy at Vanessa.Murphy@newcastle.edu.au or Karen McLaughlin on 0425277200.

Please click on the link below to proceed to the survey. If the link fails to load automatically, please cut and paste it into your internet browser: https://redcap.hmri.org.au/surveys/?s=NR78PWYW49

 

Recruiting for new study investigating the effects of ambulatory oxygen therapy via portable concentrator in interstitial lung disease

Researchers at Austin Health are currently recruiting patients with chronic interstitial lung disease and exertional desaturation (< 90% on room air during the 6-minute walk test) for a randomized controlled trial investigating the effects of ambulatory oxygen therapy via portable concentrators. Inclusion and exclusion criteria are in the link below. 

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371748&isReview=true  

If you wish to discuss possible patients for screening and enrolment or receive further information, please contact Yet Hong Khor on 03 9496 5390 or YetHong.Khor@austin.org.au.

This study has been approved by the Austin Health Human Research Ethics Committee.

 

Are you interested in helping us further our understanding of healthcare professionals’ perceptions of asthma using an innovative method – drawings?

If so, and you are a healthcare professional, you are invited to take part in a research study exploring the use of drawings to further understanding of healthcare professionals’ perceptions of the experience of asthma.

An emerging approach for investigating people’s perspectives of illness is the use of drawings. Despite the high prevalence of asthma, there is yet to be research using drawing to explore healthcare professionals’ perceptions of the experience of asthma in the Australian population. Drawings may be useful for expression and could increase our understanding of the perspective of healthcare professionals involved in asthma management. The total time commitment is expected to be approximately one hour. You will be reimbursed for your time.

If you would like more details or would like to take part, please contact the researchers (details below). Thank you!

A/Prof Lorraine Smith, Faculty of Pharmacy, The University of Sydney
Email: lorraine.smith@sydney.edu.au Telephone: 02 9036 7079

Melissa Cheung, PhD Candidate, Faculty of Pharmacy, The University of Sydney
Email: lorraine.smith@sydney.edu.au Telephone: 02 9351 3710

 

Paediatric PFT needs assessment

We are undertaking a project to assess and address the needs of the global paediatric pulmonology/respirology community for practice guidelines for paediatric pulmonary function testing in both the clinical and research settings.

The first step in this project is to define and understand those needs via a short (less than 5 minute) survey. We ask that you complete this brief survey to help us understand how to best meet the needs of our community. Please click on the link below to complete the survey online.

Survey

Thank you for your time.

Nitin Kapur, Paediatric SIG Convenor

on behalf of 

Members of the American Thoracic Society/European Respiratory Society Infant & Preschool Pulmonary Function Testing Working Group and the European Respiratory Society Pediatric Respiratory and Sleep Physiology Working Group:

Graham Hall, BSc PhD
Jessica Pittman, MD MPH
Padmaja Subbarao, MD MSc FRCP
Claudia Calogero, MD
Stephanie Davis, MD
Margaret Rosenfeld, MD MPH

 

Barriers and Facilitators to Optimal use of Acute Oxygen Therapy in Adults

Dear colleagues,

Our research  team is conducting a study to investigate the  barriers, facilitators and attitudes of health care professionals towards the prescription and delivery of oxygen therapy in the acute care setting. We hope that the results from this study will provide information that will be used to inform and facilitate the translation of evidence based guidelines into clinical practice.

As a clinician who delivers care to patients who use oxygen therapy, we understand that your views and opinions are important. You are invited to participate in this voluntary online survey. It is expected that this should take no longer than 15 minutes. There are no correct or incorrect responses, this survey is designed to explore your opinions regarding acute oxygen therapy.

This study has been granted ethics approval by Hunter New England Human Research Ethics Committee  (Approval number: 16/04/20/5.03) and the University of Newcastle Human Research Ethics Committee (Reference Number: H-2016-0222). For further information you can view the participant information HERE.

There are no anticipated risks to you for taking part in this survey. Information that you provide will be anonymous and remain confidential. Only those directly involved in this research have access to any answers that you provide. Participation in the survey implies consent and can be completed by clicking  the  OXYGEN SURVEY LINK HERE.

Please feel free to contact us directly if you have any questions regarding this research.

We thank you in advance for participating and ask you to consider forwarding this survey to other colleagues, who also deliver care to patients with oxygen therapy.

Kind Regards

Professor Vanessa McDonald
Professor Peter Wark
Joyce Cousins (PhD Scholar)
Contact: joyce.cousins@uon.edu.au

ATS Conference Review

Please CLICK HERE to view the publication by Research Review on the recent American Thoracic Society (ATS) conference.

TSANZ Recruiting Now

Administrative Officer (up to $60,000 + super)

  • Excellent working conditions
  • Access to salary sacrifice and other benefits
  • Annual leave loading
  • Flexible working conditions, friendly team and great working environment

Function: This position is responsible for providing administrative support

Reports to: Chief Executive Officer (CEO)           

Salary: $50,000-$60,000 (dependent on experience)

Permanent full time

ROLE PURPOSE: This position is responsible for providing administrative support to the New Zealand Branch, assisting the CEO in managing the activities of the office and supporting the laboratory accreditation program.

Job Accountabilities:

  1. Document management is maintained for all TSANZ controlled documents
  2. Provides a high level of administrative support to the TSANZ Board and CEO
  3. Executive officer assistance to NZ branch to support compliance with NZ legislation and constitution
  4. Undertake administrative support to the laboratory accreditation program:
  • Provide administrative support to subcommittees
  • Regular liaison with the Laboratory Accreditation Coordinator and Subcommittee Chairs to ensure effective overall management of the laboratory accreditation program
  • Check the accreditation applications against TSANZ Laboratory Manual and communicate it back to the laboratories for any major inaccuracy
  • Organise laboratory site visit including date, agenda, travel and accommodation
  • Liaise with assessor panels and laboratories on an ongoing basis to make sure they have the information and support to provide the appropriate application and  assessment
  • Ensure reports/responses from assessor panels and laboratories are received on time, and provided to the CEO and Chair LAC for moderation
  • Maintain accreditation documents including the manual, forms and other templates
  • Maintain accreditation files of each laboratory to reflect best practice in document management
  • Maintain the accredited laboratory information on the TSANZ website
  • Preparation of reports and correspondence     

KEY SELECTION CRITERIA – please address the following in your application:

  • Experience in working in an office environment
  • Must have the ability to communicate accurately and clearly both orally and in writing
  • Pleasant telephone manner
  • Able to think on feet when dealing with callers
  • Customer service oriented with a “can do” approach to work
  • Microsoft Office expertise
  • A team player who is able to work effectively as part of a small productive team and as a self-motivated individual
  • Superior organisational skills, attention to detail and problem solving skills
  • Excellent people skills
  • Experience working in a quality assured environment is advantageous

HOW TO APPLY:

Click apply or send your resume to Tanya.Buchanan@thoracic.org.au by Friday 11th August 2017

Please clearly indicate your relevant experiences and skills to this role.

Position Description: https://www.thoracic.org.au/documents/item/1044

OVERVIEW OF TSANZ: The Thoracic Society of Australia and New Zealand Ltd (TSANZ) is a company limited by guarantee and a health promotion charity (HPC) established to improve the knowledge and understanding of lung disease, to prevent respiratory illness through research and health promotion, and improving health care for people with respiratory disorders.

For details concerning this role, please contact Tanya Buchanan, Phone : 0292226205
Email : tanya.buchanan@thoracic.org.au

You must have the right to live and work in this location to apply for this job.

 

 

 

 

 
 
 
 
 
 
 
 
 

.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 2.03 APRIL 2017

Research Roundup:

April 2017

.
 

Welcome Message

Wow, what a conference! I would like to take this opportunity to thank everyone who contributed to making TSANZSRS17 a headline conference. There were many ideas shared and members celebrated. In this Research Roundup we bring to you a full list of the 2017 award winners. But this year of awards is not over yet! Please see below and online at Open Awards to find current opportunities in CF training and research, conference travel, and project support through the Lungs for Life Research Awards. 

Enjoy the April edition of your research roundup.

Prof Phil Hansbro

Chair, Research Sub-Committee

The following articles will take you to thelimbic.com

Aussie research win! The American College of Physicians have highlighted an Australian study as one of the most influential in respiratory medicine from 2016. Read More. 

First-ever pulmonary rehabilitation guidelines for Australia and New Zealand. One key message from the guidelines is that all COPD patients should be offered pulmonary rehabilitation regardless of their disease severity, guideline panel Chair Professor Jennifer Alison told the limbicRead More.

Hidden population at risk of thunderstorm asthma. Many more people than previously thought are at risk of thunderstorm asthma, particularly people who have hay fever, a survey reveals. Read More.

Doctor deaths prompt further investigation. NSW Health Minister Brad Hazzard has asked his department to report back within four weeks with advice on how to make hospitals a safer workplace for junior doctors. Read More. 

Respiratory nurses agree they have a role in advance care planning. But tension still exists about how and when to initiate conversations with patients, Dr Rebecca Disler told conference delegates. Read More. 

Short on drug options for shortness of breath. Morphine is still the best pharmacological treatment for chronic breathlessness, according to an extensive review of the literature. Read More.

GPs too passive in approach to COPD. GPs hold back on formerly diagnosing people with COPD and delay offering interventions such as smoking cessation or pulmonary rehabilitation, a survey shows. Read More.

New hope for people with IPF. Evidence is building for the non-pharmacological management of idiopathic pulmonary fibrosis including ambulatory oxygen and pulmonary rehabilitation, Professor Anne Holland told the conference this afternoon during a plenary session on novel therapies in IPF. Read More. 

2017 Award Winners

Presented at the 2017 TSANZ ASM in Canberra

Thoracic Society Medals

Laennec Medal – presented to the outgoing TSANZ President, Prof Peter Gibson

Society Medal – presented to A/Prof Peter Holmes

50th Anniversary Medal – presented to Prof Jennifer Alison and Prof Richard Ruffin

President’s Award – presented to Dr Becky Freeman

Wunderly Oration – delivered by Prof Jennifer Martin

Fellowships

TSANZ / National Asthma Council Australia – Asthma and Airways Career Development Fellowship – presented to Dr Adam Collison

2016 Vertex Adult Cystic Fibrosis  Fellowship – presented to Dr Anna Tai

Lung Foundation Australia / Boehringer Ingelheim COPD Research Fellowship 2017/2018 – presented to Dr Anna Hudson

Abstract-linked Awards

TSANZ Janet Elder Early Career Travel Awards – presented to Dr Luke Garratt and Dr Jade Jaffar

TSANZ Janet Elder Mid Career Travel Award – presented to Prof Lisa Wood

TSANZ / Japanese Respiratory Society Early Career Travel Award – presented to Dr Eugene Roscioli

TSANZ / Boehringer Ingelheim COPD Travel Award – presented to Dr Eskandarain Shaffudin

Ann Woolcock New Investigator Finalists

Tim Rosenow, Telethon Kids, University of Western Australia
Simone Barry, Royal Adelaide Hospital
Eugene Roscioli, Royal Adelaide Hospital, Lung Research Laboratory
Thomas Iosifidis, University of Western Australia [Winner]
Rhiannon Werder, University of Queensland
Phillipa Southwell, Charles Sturt University

Research Project Support Awards

2016 Boehringer Ingelheim COPD Research Award – presented to A/Prof Greg Hodge and Prof Sandra Hodge

2017 Boehringer Ingelheim COPD Research Award – presented to Dr Maria Sukkar and Dr Jane Bourke

Maurice Blackburn Grant-in-Aid for Asbestos Research – presented to Prof Steve Mutsaers

AstraZeneca Grant-in-Aid for Severe Asthma – presented to Dr Fatemeh Moheimani

TSANZ Robert Pierce Grant-in-Aid for Indigenous Lung Health – presented to Dr Holly Clifford

Lung Foundation Australia / Ivan Cash Research Grant-in-Aid Award – presented to Dr Yet Hong Khor

Lung Foundation Australia / Lizotte Family Research Award – presented to Dr Michael Schuliga

Lung Foundation Australia / Ludwig Engel Grant-in-Aid for Physiological Research – presented to Prof Peter Middleton

Australian Cystic Fibrosis Research Trust 2017 Innovation Grant – presented to Dr Jay Horvat, Prof Peter Wark, and Prof Phil Hansbro

Travel Awards

TSANZ Peter Phelan Travel Fellowship – presented to Dr Kimberley Wang

TSANZ Respiratory Nurse Career Development Award for Indigenous Research – presented to Ms Erin Plumb

Special Interest Group Awards

  • TSANZ Best Poster Prize (supported by Boehringer Ingelheim) – presented to David Chapman
  • Asthma & Allergy (supported by National Asthma Council Australia) – presented to Joy Lee
  • Asthma & Allergy (supported by Asthma Australia) – presented to James Pinkerton
  • OELD/Population Health (supported by Maurice Blackburn ) – presented to Holly Clifford
  • Lung Cancer (supported by Maurice Blackburn) – presented to Koliarne Tong
  • COPD (supported by Boehringer Ingelheim) – presented to Steven Maltby
  • OLIV (supported by Boehringer Ingelheim) – presented to Rebecca Harper
  • Primary Care (supported by Boehringer Ingelheim) – presented to Juliet Foster
  • Respiratory Nurses Oral (supported by Boehringer Ingelheim) – to co-presenters Mary Roberts and Vinita Swami
  • Pulmonary Physiology and Sleep, John Reid Prize (supported by Lung Foundation Australia) – presented to Mahesh Dharmakamara
  • David Serisier Memorial Award 2016 for Translational Research – Respiratory Infectious Disease (supported by Lung Foundation Australia) – presented to Su-Ling Loo
  • Cystic Fibrosis (Supported by Cystic Fibrosis Australia) – presented to Michelle Wood
  • Cell biology/Immunology – Andrew Reid
  • Evidence Based Medicine – presented to Narelle Cox
  • Interventional Pulmonology – presented to Arash Badiei
  • Peter van Asperen Paediatric Award – presented to Ajay Kevat
  • Physiotherapy – presented to Sally Wootton
  • Tobacco Control – presented to Jenifer Liang

Open Awards

Vertex Awards

Vertex Paediatric Cystic Fibrosis Clinical Fellowship

The TSANZ Vertex Cystic Fibrosis Paediatric Clinical Fellowship supports an articulated training program for advanced trainees who are currently, or who wish to sub-specialize in Paediatric Respiratory Medicine, specifically to conduct the research, diagnosis and management of cystic fibrosis in Australia and New Zealand.

This is a unique opportunity to secure a fellowship that supports clinic based training in a Paediatric specialty area.

The fellowship shall be to the value of AUD$50,000 per annum for two years.

Vertex Adult Cystic Fibrosis Fellowship

The TSANZ Vertex Adult Cystic Fibrosis Fellowship will support a health practitioner or research scientist working in respiratory medicine who wishes to undertake research into adult cystic fibrosis, accompanied with professional development in adult cystic fibrosis in Australia or New Zealand.

This is a unique opportunity to secure a fellowship that supports either research and/or clinic based training / professional development in the adult cystic fibrosis specialty area.

The fellowship shall be to the value of AUD$50,000 per annum for two years.

Vertex Cystic Fibrosis Research Awards

To foster ongoing original cystic fibrosis research and its communication internationally.

The winners of the awards (2) will receive an award up to the value of AUD$7500 each to support their economy class travel, registration and accommodation to present their research at the European Cystic Fibrosis Society Annual Meeting or the North American Cystic Fibrosis Conference.

Lungs for Life Awards

Lungs for Life Research Awards

This Research Award aims to provide seed funding for critical and impactful areas of respiratory research. Preference will be given to research proposals in the priorities areas of early lung development, infection, and lung cancer. Three research proposals will be funded.

The Research Award value will total $40,000. Funds will be offered as $20,000 from Lungs for Life and must be matched with equal or greater funding from the applicant’s institution.

Lung Foundation Awards

Lung Foundation Australia / A Menarini Pty Ltd 2017 Travel Awards

Lung Foundation Australia and A Menarini Australia Pty Ltd are excited to announce that there will be six (6) Travel Grants of up to $3,000 for international conferences and up to $1,500 for national conferences on offer to health professionals/researchers in Australia whose work is focused on improving outcomes for patients living with COPD.

Watch this space for more award announcements…

Lungs for Life Grant Bulletin

The Lungs for Life project has identified the following direct-to-researcher grants and awards due between late April and mid-2017:

Association for International Cancer Research Grants – 21/04/17
Project grants of between one and three years to support fundamental and translational research into the causes, mechanisms, diagnosis, treatment and prevention of cancer. Proposals in which a mixture of basic and clinical research is proposed will be considered.

The Rebecca L. Cooper Medical Research Foundation Al and Val Rosenstrauss Medical Research Fellowship – closes 28/04/17
The Al and Val Rosenstrauss Research Fellowships are named in honour of the late Al Rosenstrauss OAM and his wife, Val, for their contribution to the work of the Foundation over a period of more than 28 years. Research project must be in one of the nominated areas of medical research that are supported by the Foundation; Brain Sciences, Diabetes, Geriatrics, Lung Disease (other than cancer), Rheumatology, and Vision Sciences. Applicants who have received previous funding, or worked in a laboratory supported by the Foundation, will be favoured.

The Bioinformatics Peer Prize – closes 30/04/17
In partnership with the Centre for Systems Genomics at the University of Melbourne, The Australian Regenerative Medicine Institute at Monash University & Melbourne Bioinformatics, Thinkable is excited to launch the inaugural ‘Peer Prize’ for bioinformatics. The objective is to accelerate wider knowledge exchange & drive multi-disciplinary collaboration with the latest bioinformatics research from around the world, while celebrating the most exciting new discoveries made in the field as voted by peers.

Sylvia and Charles Viertel Charitable Foundation Clinical Investigatorships – closes 30/04/17
To stimulate and encourage clinical research in Australia. In particular the grants are intended to assist new investigators to establish their research programs at the time of the difficult transition from doctoral and post-doctoral training posts to their first definitive clinical positions in an academic environment.

Sylvia and Charles Viertel Charitable Foundation Senior Medical Research Fellowship – closes 30/04/17
Providing salary and project grant support for outstanding medical researchers.

Bill & Melinda Gates Foundation Grand Challenges Explorations Round 19 – closes 11/05/17
Early-stage innovative research projects from a range of disciplines and regions.

Winston Churchill Memorial Trust Fellowship – closes 15/05/17
To provide an opportunity for Australians to travel overseas (for 4 – 6 weeks) to conduct research in their chosen field that is not readily available in Australia.

The Prince Charles Hospital Foundation Experienced Researcher Project Grants – closes 20/05/17
To support strategic, world-class, sophisticated research on the Foundation’s campus or in significant partnership with this campus in the priority areas of: Heart disease – heart failure, valvular heart disease, congenital heart disease; Lung disease – lung cancer, asbestos related diseases, COPD, pulmonary hypertension, cystic fibrosis, sleep disorders, asthma; Dementia – Alzheimer’s disease, vascular dementia, Lewy Body disease, fronto-temporal dementia; Arthritis – osteoarthritis, joint replacement, growing cartilage.

Australian Institute of Policy and Science – CSL Florey Medal – closes 28/05/17
Award for an Australian biomedical researcher with significant achievements in biomedical science and/or human health advancement for research conducted primarily in Australia. Winners are expected to attend a presentation ceremony in Canberra in November.

The NVIDIA Foundation Compute the Cure Cancer Research Grants – closes 28/05/17
To advance the fight against cancer. Will fund projects that use computational omics to dramatically impact the battle against cancer and reduce the time it takes for research outcomes to be used effectively in a clinical environment.

Australian Institute of Policy and Science – CSL Young Florey Medal – closes 06/06/17
Award for an Australian biomedical researcher with significant early career achievements in biomedical science and/or human health advancement. Selection Criteria: Excellence in research achievement in the biomedical science and/or human health advancement; and Excellence and passion in communication and community engagement to promote understanding and engagement in science.

Wellcome Trust Pathfinder Awards – closes 20/06/17
The diagnosis, prevention and treatment of orphan and neglected diseases that present an unmet medical need. Seeking to fund pilot studies to develop assets and de-risk future development.

Australian Cancer Research Foundation (ACRF) Cancer Research Grants – closes 23/06/17
Seeks to support all aspects of cancer research and control including but not limited to: cell or molecular biology, epidemiology, early detection, prevention and drug development. Focused on seed funding; primarily providing capital grants for major equipment, and the establishment of capital works and facilities. Collaborative projects between institutions are encouraged.

John T Reid Charitable Trusts – closes 28/06/17
The John T Reid Charitable Trusts is a national funding organisation with a wide ranging commitment to philanthropy around Australia. Funding focus is on community and social welfare, health support, aged and palliative care, education and youth support, arts and cultural heritage and the environment.

The Sir Robert Menzies Memorial Research Scholarship in the Allied Health Sciences – closes 30/06/17
The purpose of the scholarship is to try to improve the health of Australians by supporting an outstanding applicant from one of the non‐medical allied health disciplines, or from an applicant who is working directly in applied clinical research.

The John Burge Trust – closes 30/06/17
The John Burge Trust was established by the late John Burge to assist people with tuberculosis and support work towards the prevention and cure of the disease. This can include: educational programs for health workers; aid and help for tuberculosis sufferers and who by reason of the disease are disabled; medication; research.

Shepherd Foundation Research Grants – closes 01/07/17 and 15/09/17
For research projects in all aspects of preventative medicine and/or occupational medicine. Applicants may apply for funding of one, two or three years.

Lung Cancer Research Foundation Grants 2017 – closes 01/07/17
Lung cancer projects focused on one or more of the following: basic science; translational research; clinical research; supportive care; quality of care/outcomes.

The Alan Westcare Project Grant – closes 31/07/17
The Alan King Westcare Project Grant is a 12 month $50,000 grant to available to laboratory, clinical and epidemiological research into the cause, diagnosis, prevention and treatment of respiratory infections such as tuberculosis.

CSL Centenary Fellowships 2017 – closes 31/07/17
To foster excellence in Australian medical research by supporting mid-career Australian scientists to pursue world class medical research. The fellowship provides for a full-time salary (generally equivalent to a Senior Research Fellow C1 level) plus research costs and/or a post-doctoral research assistant. The breakdown is determined by the Fellow, in conjunction with the employing institution at the commencement of the Fellowship. The fellowships are primarily awarded for discovery and translational research with a focus on rare and serious diseases, immunology, and inflammation. However, those who meet the eligibility are strongly encouraged to submit an application for their medical research project.

Government of Western Australia – 2017 Healthway Intervention Research Grants – closing date TBA
Intervention Research Grants will fund applications that demonstrate a clear pathway to a health promotion program or intervention in WA, including policy interventions. Applicants are required to focus on at least one of Healthway’s priority areas of tobacco smoking control, reducing harm from alcohol, good nutrition promotion, physical activity promotion (including reducing sedentary behaviour), mental health promotion, skin cancer prevention, reducing harm from illicit drugs and Aboriginal health. Applications in other areas of health promotion will not be considered.

Rolling Grants

Advance Queensland Founders’ Fellowships – closes 12/05/17 (quarter one round)
To support entrepreneurial scientists, researchers and clinicians to take 12 months away from their normal job to develop their early stage novel and innovative ideas with commercialisation prospects into new products, processes or services.

Boehringer Ingelheim Fonds Travel Grants
Grants for non-European researchers to travel to Europe for up to three months to pursue an experimental project in basic biomedical research.

Baxalta Bioscience Grants – Medical Education & Fellowship Grants
Baxalta provides Medical Education & Fellowship Grants to support accredited or unaccredited educational symposia, seminars, web-based sessions, or fellowship programs directed at certified healthcare professionals. They are currently interested in supporting the following areas: Immunology; Hematology; Oncology.

Coopers Brewery Foundation – current round closes 01/08/2017
Medical research and health care; educational development for the young; aged care; promotion of family and community support based on Christian values.

The Balnaves Foundation
The Balnaves Foundation supports organisations that aim to create a better Australia through education, medicine and the arts with a focus on young people, the disadvantaged, and Indigenous communities.

 

Respirology

Respirology Issue 22.3

Association between asthma control and asthma cost: Results from a longitudinal study in a primary care setting

By Nguyen et al. (resp.12930/ RES-16-407.R2)

 

Singhealth Duke-NUS Research team members from Canada and Singapore. Left to right:Lye Weng Kit, Dr Ngiap C. Tan, Dr. Nivedita V. Nadkarni, Usha Sankari, Dr Hai V. Nguyen and Shweta Mital.

 

YKL-40, CCL18 and SP-D predict mortality in patients hospitalized with community-acquired pneumonia

By Spoorenberg et al. (resp12924/RES-16-449.R1)

 

CAP study group members from St Antonius Hospital in Nieuwegein, The Netherlands.

Left to right: Willem Jan Bos, Simone Spoorenberg, Stefan Vestjens and Jan Grutters.

 

Respirology Issue 22.4

Home-based telerehabilitation via real-time videoconferencing improves endurance exercise capacity in patients with COPD: The randomized controlled TeleR Study

LING LING Y. TSAI, RENAE J. MCNAMARA, CHLOE MODDEL, JENNIFER A. ALISON, DAVID K. MCKENZIE AND ZOE J. MCKEOUGH   

(DOI: 10.1111/resp.12966)

 

The respiratory telerehabilitation (TeleR) trial team from Sydney, Australia

 

Nasal lavage, blood or sputum: Which is best for phenotyping asthma?

CAMYLA F. DE FARIAS, MARIA M.F. AMORIM, MICHEL DRACOULAKIS, LILIAN B. CAETANO, ILKA L. SANTORO AND ANA L.G. FERNANDES

(DOI: 10.1111/resp.12958)

 

The Asthma Group EPM-Unifesp from São Paulo, Brazil. Left to right: Danilla Assad Fernandes, Lilian Ballini Caetano, Michel Dracoulakis, Patricia Bueno Fernandes, Fabiana Stanzani, Camyla Fernandes, Maria Amélia Carvalho Santos, Ana Luisa Godoy Fernandes, Maria Marta Amorim.

Australasian Clinical Tuberculosis Network (ACTnet)

The Australasian Clinical Tuberculosis Network (ACTnet) is a collaborative clinical research group spanning Australia and New Zealand. Following the successful model of the European “TBnet” collaboration (www.tb-net.org), ACTnet will engage clinicians and researchers across the two countries to conduct high-quality research of national and international significance. It will provide a platform for individual investigators, within infectious disease, respiratory, public health and other disciplines, to propose and implement multi-centre studies and laboratory collaborations.

ACTnet aims to promote basic science, clinical and public health research into TB in Australia and New Zealand. We will be working in partnership to create the knowledge required to eliminate TB in Australia, New Zealand and beyond.

We are inviting TSANZ members to join our network. There are a variety of ways you can contribute to the growth of this network but becoming a member is the first step.  Please see our website www.actnet.org.au  further details and if interested click on the ‘Become a member’ sign up box on the home page.

Alternatively you can send an email to elyse.guevara-rattray@sydney.edu.au the ACTnet Network Officer. ACTnet is supported by ARC, TSANZ, ASID and TBForum.

Research Project and Survey Requests 

Recruiting for new study investigating the effects of ambulatory oxygen therapy via portable concentrator in interstitial lung disease

Researchers at Austin Health are currently recruiting patients with chronic interstitial lung disease and exertional desaturation (< 90% on room air during the 6-minute walk test) for a randomized controlled trial investigating the effects of ambulatory oxygen therapy via portable concentrators. Inclusion and exclusion criteria are in the link below. 

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371748&isReview=true  

If you wish to discuss possible patients for screening and enrolment or receive further information, please contact Yet Hong Khor on 03 9496 5390 or YetHong.Khor@austin.org.au.

This study has been approved by the Austin Health Human Research Ethics Committee.

 

Are you interested in helping us further our understanding of healthcare professionals’ perceptions of asthma using an innovative method – drawings?

If so, and you are a healthcare professional, you are invited to take part in a research study exploring the use of drawings to further understanding of healthcare professionals’ perceptions of the experience of asthma.

An emerging approach for investigating people’s perspectives of illness is the use of drawings. Despite the high prevalence of asthma, there is yet to be research using drawing to explore healthcare professionals’ perceptions of the experience of asthma in the Australian population. Drawings may be useful for expression and could increase our understanding of the perspective of healthcare professionals involved in asthma management. The total time commitment is expected to be approximately one hour. You will be reimbursed for your time.

If you would like more details or would like to take part, please contact the researchers (details below). Thank you!

A/Prof Lorraine Smith, Faculty of Pharmacy, The University of Sydney
Email: lorraine.smith@sydney.edu.au Telephone: 02 9036 7079

Melissa Cheung, PhD Candidate, Faculty of Pharmacy, The University of Sydney
Email: lorraine.smith@sydney.edu.au Telephone: 02 9351 3710

 

Paediatric PFT needs assessment

We are undertaking a project to assess and address the needs of the global paediatric pulmonology/respirology community for practice guidelines for paediatric pulmonary function testing in both the clinical and research settings.

The first step in this project is to define and understand those needs via a short (less than 5 minute) survey. We ask that you complete this brief survey to help us understand how to best meet the needs of our community. Please click on the link below to complete the survey online.

Survey

Thank you for your time.

Nitin Kapur, Paediatric SIG Convenor

on behalf of 

Members of the American Thoracic Society/European Respiratory Society Infant & Preschool Pulmonary Function Testing Working Group and the European Respiratory Society Pediatric Respiratory and Sleep Physiology Working Group:

Graham Hall, BSc PhD
Jessica Pittman, MD MPH
Padmaja Subbarao, MD MSc FRCP
Claudia Calogero, MD
Stephanie Davis, MD
Margaret Rosenfeld, MD MPH

 
 

 

 

 

 
 
 
 
 
 
 
 
 

.

VOLUME 6.02 – FEBRUARY 2021

VOLUME 1.08 OCTOBER 2016

Research Roundup:

October 2016

.
 

Welcome Message

Abstract submissions for the TSANZSRS 2017 close tomorrow! Please submit your abstracts and look into applying for the abstract-linked awards.

We are now happy to announce that TSANZ has finalised an en bloc membership agreement with the ERS. Membership to the European Respiratory Society will be available to all TSANZ members upon renewal of your TSANZ membership, at an additional heavily discounted rate. This will give members who choose to take out ERS membership highly discounted member benefits including access to the digital ERS Journal, international ERS awards, and various discounted rates, such as for the ERS Congress.

There is also good news for COPD researchers. We have now opened the new Boehringer ingelheim COPD Research Award. This award will build capacity and foster the development of research in the area of COPD through the support of pilot studies, proof of concept and feasibility studies. Please see below for more detail or visit our awards page.

Lastly, I urge you once again to look to the surveys section of this newsletter. Please support your fellow TSANZ researchers and consider participating in these. We all know how difficult collecting the necessary data can be and this is a good opportunity for collegiate support. 

Enjoy your October Research Roundup,

Prof Phil Hansbro

Chair, Research Sub-Committee

Special Awards and Fellows

Nominations for the TSANZ Research medal are now open to all members of TSANZ. The Research Medal is awarded in recognition of outstanding contributions to the advancement of knowledge in respiratory medicine or science carried out primarily in Australia or New Zealand.

The award recognises an individual who has demonstrated sustained excellence in their field of research and is open to all financial members of TSANZ, including Associate members. Please consider nominating yourself or a Colleague for this prestigious award.

The Society Medal and 50th Anniversary Medal for education applications are also open.
For more information http://www.thoracic.org.au/researchawards/tsanz-awards-by-nomination 
Nominations close: 24th November

A call for TSANZ Fellows is currently open to members from all professions who demonstrate exceptional contribution to the field of respiratory health in Australia or New Zealand. If the Fellow status is approved, the member will be able to use the post nominal FThorSoc and will be able to continue to do so whilst a financial member of TSANZ.The main aims of the Fellow status are:

1. To recognise expertise and experience in respiratory medicine and/or research and/or respiratory health service provision.
2. To acknowledge a major contribution and commitment to advancing respiratory health in Australia and/ or New Zealand.

Applications close 24th November. Please see http://www.thoracic.org.au/about-us/fellow-of-thoracic-society-australia-new-zealand for more info.

The following articles will take you to thelimbic.com

Thoracic items targeted in MBS review. Proposed changes to spirometry and sleep study items will address problems of under-utilisation of spirometry and over-utilisation of sleep studies as well as better remunerate health care professionals. Read More. 

Holy grail: Reducing the burden of asthma in South Australia. In this month’s Holy Grail Dr Kristen Carson, a Senior Medical Research Scientist at The Queen Elizabeth Hospital in Adelaide, tells us about her work creating an evidence-based solution to reducing the high rate of asthma related hospitalisations in South Australia. Read More.

Simple home based pulmonary rehab offers hope for some COPD patients. Home-based pulmonary rehabilitation delivered using minimal resources has similar – and in some cases even superior – outcomes to centre-based pulmonary rehabilitation, Australian researchers have found. Read More.

Experts still think more is not better. Australian and New Zealand experts have reiterated their rationale for a target oxygen saturation range of 92-96% instead of the British Thoracic Society recommendation of 94-98%. Read More.

Black lung crisis escalates. A 54-year-old coal miner from Queensland has been confirmed as the 15th case of pneumoconiosis following a re-emergence of the disease last year. Read More.

Potential role for Vitamin D in asthma. A Cochrane review has provided more robust evidence that adding vitamin D supplements to routine asthma management plans may benefit patients. We caught up with the lead author to find out more. Read More.

+ Experts respond. They note that the finding that vitamin D protected against severe asthma attacks is based mainly on results from adults and may not be applicable to children. Read More.

Travel opportunities for APSR Young Investigator members

Award opportunities for APSR Young Investigator members to participate in the APSR-ISRD Joint Session at ATS International Conference, Washington DC in 2017.

Individuals who submit an abstract to ATS 2017 will have a chance to receive a travel award.

View the APSR flyer for more information 

Research Project and Survey Requests

Barriers and facilitators to optimal use of acute oxygen therapy in adults

Dear colleagues,

Our research  team is conducting a study to investigate the  barriers, facilitators and attitudes of health care professionals towards the prescription and delivery of oxygen therapy in the acute care setting. We hope that the results from this study will provide information that will be used to inform and facilitate the translation of evidence based guidelines into clinical practice.

As a clinician who delivers care to patients who use oxygen therapy, we understand that your views and opinions are important. You are invited to participate in this voluntary online survey. It is expected that this should take no longer than 15 minutes. There are no correct or incorrect responses, this survey is designed to explore your opinions regarding acute oxygen therapy.

This study has been granted ethics approval by Hunter New England Human Research Ethics Committee  (Approval number: 16/04/20/5.03) and the University of Newcastle Human Research Ethics Committee (Reference Number: H-2016-0222). For further information you can view the participant information HERE

There are no anticipated risks to you for taking part in this survey. Information that you provide will be anonymous and remain confidential. Only those directly involved in this research have access to any answers that you provide. Participation in the survey implies consent and can be completed by clicking  the  OXYGEN SURVEY LINK HERE

Please feel free to contact us directly if you have any questions regarding this research.

We thank you in advance for participating and ask you to consider forwarding this survey to other colleagues, who also deliver care to patients with oxygen therapy.

Kind Regards

Professor Vanessa McDonald
Professor Peter Wark
Joyce Cousins (PhD Scholar)
Contact: joyce.cousins@uon.edu.au

Inhaled Liposomal Amikacin for treatment resistant MAC infection – a randomised control trial enrolling now.

Dear TSANZ members,
There is currently an industry sponsored RCT of Nebulised Liposomal Amikacin for pulmonary MAC infection which has failed six months of standard therapy or relapsed after treatment. This is the first RCT of a novel compound for NTM infection. Inclusion and exclusion criteria are in the link below.

https://clinicaltrials.gov/ct2/show/NCT02344004?term=LAI&rank=3

The CONVERT STUDY is an international, multi-centre study and there are a number of study sites in Australia and New Zealand. The study sponsor is prepared to pay for travel and accommodation expenses for people in regional areas to travel to study sites.
If you wish to discuss possible patients for screening and enrolment, I can be contacted via email at andrew.burke@health.qld.gov.au, and I can direct you to your nearest study site.

Dr Andrew Burke
Thoracic and Infectious Diseases Physician
The Prince Charles Hospital, Brisbane
(study PI, no conflicts)

Perioperative care of patients with OSA: A survey of beliefs and management approaches amongst Australian clinicians

Obstructive sleep apnoea (OSA) has a rising prevalence in the general population and in those presenting for surgery. It is an established risk factor for increased incidence of peri-operative and post-operative complications. There are currently no consensus-based recommendations on management of these patients in Australia. We wish to conduct a survey of specialties involved in the care of these patients to examine current practice and beliefs in the perioperative management of OSA. The results will be reviewed by the Respiratory and Sleep Department at St Vincent’s Hospital Melbourne, to identify  current trends in practice, and to ultimately guide towards a consensus approach in this field.

The survey link is: https://www.surveymonkey.com/r/perioposa

Dr Chong Weng Ong | Respiratory and Sleep Consultant | St Vincent’s Hospital Melbourne

Joy Sha | Respiratory and Sleep Registrar | St Vincent’s Hospital Melbourne

COPD survey invitation for Physio, Primary Care and Respiratory Nurse SIG

Dear Colleague

Our research team is conducting a survey to understand physiotherapist’s, occupational therapist’s, nurse’s, social worker’s and other allied health professionals’ knowledge and practice behaviours regarding advance care planning in patients with COPD. From the results of this study we hope to develop educational resources to assist health professionals when caring for this patient group.

We invite to participate in a survey, that should take only 10-15 minutes to complete. Several disciplines are represented in the overall survey, however you will be directed to only those questions relevant to your discipline.

Ethics approval has been granted for this study from the University of Sydney. All responses will be anonymous and confidential. No personal information that could identify you is being collected and your email address will not be linked to your survey response. Your consent to participate in this study is implied by completing the survey.

Further information about this research study is provided in the enclosed document [DOWNLOAD]. If you have any questions regarding this research, please do not hesitate to contact Dr Rebecca Disler directly. Thank you in advance for participating.

Please click on the link below to proceed to the survey. If the link fails to load automatically, please cut and paste it into your internet browser: https://www.surveymonkey.com/r/ACPHealthProf

Kind regards

Dr Rebecca Disler | Senior Lecturer in Chronic Disease | The University of Sydney
Email:
 rebecca.disler@sydney.edu.au  | Tel: 0406 876 587

Dr Natasha Smallwood | Respiratory Physician Department of Respiratory Medicine | The Royal Melbourne Hospital

A/Prof Louis Irving | Respiratory Physician Department of Respiratory Medicine | The Royal Melbourne Hospital
Prof David Currow | Palliative Care Physician Flinders University | Adelaide

STUDENT DECLARATION  Yuxiu Cui will be analysing the study results as the basis for her degree of Bachelor of Advanced Nursing (Honours) at The University of Sydney. This will take place under the supervision of Dr Rebecca Disler.

 
 
 

 

 

 

 
 
 
 
 
 
 
 
 

.

WHY JOIN US?

Become part of a network of professionals working in respiratory and lung health clinical care and treatment, research, health promotion and advocacy.

By browsing our website you agree to our use of cookies outlined in our revised Privacy Policy and Terms & Conditions.

X